id	sid	tid	token	lemma	pos
dhrp-67	1	1	volume	volume	NOUN
dhrp-67	1	2	2	2	NUM
dhrp-67	1	3	no	no	NOUN
dhrp-67	1	4	.	.	PUNCT
dhrp-67	2	1	s3	s3	NOUN
dhrp-67	2	2	:	:	PUNCT
dhrp-67	2	3	second	second	ADJ
dhrp-67	2	4	quarter	quarter	NOUN
dhrp-67	2	5	editorial	editorial	PROPN
dhrp-67	2	6	https://doi.org/10.47488/dhrp.v2is3.67	https://doi.org/10.47488/dhrp.v2is3.67	PROPN
dhrp-67	2	7	dhr	dhr	PROPN
dhrp-67	2	8	proceedings	proceeding	NOUN
dhrp-67	2	9	ǀ	ǀ	ADP
dhrp-67	2	10	http://dhrproceedings.org	http://dhrproceedings.org	PROPN
dhrp-67	2	11	2022	2022	NUM
dhrp-67	2	12	,	,	PUNCT
dhrp-67	2	13	vol	vol	NOUN
dhrp-67	2	14	.	.	NOUN
dhrp-67	2	15	2	2	NUM
dhrp-67	3	1	no	no	NOUN
dhrp-67	3	2	.	.	PUNCT
dhrp-67	4	1	s3	s3	PROPN
dhrp-67	4	2	1	1	NUM
dhrp-67	4	3	-	-	SYM
dhrp-67	4	4	9	9	NUM
dhrp-67	4	5	1	1	NUM
dhrp-67	4	6	editorial	editorial	NOUN
dhrp-67	4	7	paxlovid	paxlovid	PROPN
dhrp-67	4	8	rebound	rebound	PROPN
dhrp-67	4	9	:	:	PUNCT
dhrp-67	4	10	proposed	propose	VERB
dhrp-67	4	11	strategy	strategy	NOUN
dhrp-67	4	12	to	to	PART
dhrp-67	4	13	prevent	prevent	VERB
dhrp-67	4	14	reinfection	reinfection	NOUN
dhrp-67	4	15	following	follow	VERB
dhrp-67	4	16	treatment	treatment	NOUN
dhrp-67	4	17	of	of	ADP
dhrp-67	4	18	covid-19	covid-19	PROPN
dhrp-67	4	19	positive	positive	ADJ
dhrp-67	4	20	nonhospitalized	nonhospitalize	VERB
dhrp-67	4	21	patients	patient	NOUN
dhrp-67	4	22	sohail	sohail	PROPN
dhrp-67	4	23	rao	rao	PROPN
dhrp-67	4	24	,	,	PUNCT
dhrp-67	4	25	md	md	PROPN
dhrp-67	4	26	,	,	PUNCT
dhrp-67	4	27	ma	ma	PROPN
dhrp-67	4	28	,	,	PUNCT
dhrp-67	4	29	dphil,1	dphil,1	ADJ
dhrp-67	4	30	and	and	CCONJ
dhrp-67	4	31	manish	manish	PROPN
dhrp-67	4	32	singh	singh	PROPN
dhrp-67	4	33	,	,	PUNCT
dhrp-67	4	34	md	md	PROPN
dhrp-67	4	35	,	,	PUNCT
dhrp-67	4	36	facs	fac	NOUN
dhrp-67	4	37	,	,	PUNCT
dhrp-67	4	38	fasmbs2	fasmbs2	PROPN
dhrp-67	4	39	1executive	1executive	NUM
dhrp-67	4	40	vice	vice	NOUN
dhrp-67	4	41	president	president	NOUN
dhrp-67	4	42	for	for	ADP
dhrp-67	4	43	research	research	PROPN
dhrp-67	4	44	&	&	CCONJ
dhrp-67	4	45	leadership	leadership	PROPN
dhrp-67	4	46	development	development	NOUN
dhrp-67	4	47	,	,	PUNCT
dhrp-67	4	48	dhr	dhr	PROPN
dhrp-67	4	49	health	health	PROPN
dhrp-67	4	50	,	,	PUNCT
dhrp-67	4	51	5501	5501	NUM
dhrp-67	4	52	s.	s.	PROPN
dhrp-67	4	53	mccoll	mccoll	PROPN
dhrp-67	4	54	road	road	PROPN
dhrp-67	4	55	,	,	PUNCT
dhrp-67	4	56	edinburg	edinburg	PROPN
dhrp-67	4	57	,	,	PUNCT
dhrp-67	4	58	texas	texas	PROPN
dhrp-67	4	59	78539	78539	NUM
dhrp-67	4	60	,	,	PUNCT
dhrp-67	4	61	and	and	CCONJ
dhrp-67	4	62	founding	found	VERB
dhrp-67	4	63	president	president	NOUN
dhrp-67	4	64	&	&	CCONJ
dhrp-67	4	65	chief	chief	ADJ
dhrp-67	4	66	executive	executive	ADJ
dhrp-67	4	67	officer	officer	NOUN
dhrp-67	4	68	,	,	PUNCT
dhrp-67	4	69	dhr	dhr	PROPN
dhrp-67	4	70	health	health	PROPN
dhrp-67	4	71	institute	institute	PROPN
dhrp-67	4	72	for	for	ADP
dhrp-67	4	73	research	research	PROPN
dhrp-67	4	74	&	&	CCONJ
dhrp-67	4	75	development	development	PROPN
dhrp-67	4	76	,	,	PUNCT
dhrp-67	4	77	5323	5323	NUM
dhrp-67	4	78	s.	s.	PROPN
dhrp-67	4	79	mccoll	mccoll	PROPN
dhrp-67	4	80	road	road	PROPN
dhrp-67	4	81	,	,	PUNCT
dhrp-67	4	82	edinburg	edinburg	PROPN
dhrp-67	4	83	,	,	PUNCT
dhrp-67	4	84	texas	texas	PROPN
dhrp-67	4	85	78539	78539	NUM
dhrp-67	4	86	.	.	PUNCT
dhrp-67	5	1	orcid	orcid	NOUN
dhrp-67	5	2	:	:	PUNCT
dhrp-67	5	3	https://orcid.org/0000-0001-5027-9992	https://orcid.org/0000-0001-5027-9992	PROPN
dhrp-67	5	4	2dhr	2dhr	PROPN
dhrp-67	5	5	health	health	NOUN
dhrp-67	5	6	bariatric	bariatric	ADJ
dhrp-67	5	7	and	and	CCONJ
dhrp-67	5	8	metabolic	metabolic	NOUN
dhrp-67	5	9	institute	institute	NOUN
dhrp-67	5	10	and	and	CCONJ
dhrp-67	5	11	chief	chief	ADJ
dhrp-67	5	12	executive	executive	ADJ
dhrp-67	5	13	officer	officer	NOUN
dhrp-67	5	14	,	,	PUNCT
dhrp-67	5	15	dhr	dhr	PROPN
dhrp-67	5	16	health	health	PROPN
dhrp-67	5	17	,	,	PUNCT
dhrp-67	5	18	5501	5501	NUM
dhrp-67	5	19	s.	s.	PROPN
dhrp-67	5	20	mccoll	mccoll	PROPN
dhrp-67	5	21	road	road	PROPN
dhrp-67	5	22	,	,	PUNCT
dhrp-67	5	23	edinburg	edinburg	PROPN
dhrp-67	5	24	,	,	PUNCT
dhrp-67	5	25	texas	texas	PROPN
dhrp-67	5	26	78539	78539	NUM
dhrp-67	5	27	and	and	CCONJ
dhrp-67	5	28	dhr	dhr	PROPN
dhrp-67	5	29	health	health	PROPN
dhrp-67	5	30	bariatric	bariatric	PROPN
dhrp-67	5	31	&	&	CCONJ
dhrp-67	5	32	metabolic	metabolic	PROPN
dhrp-67	5	33	institute	institute	PROPN
dhrp-67	5	34	,	,	PUNCT
dhrp-67	5	35	5500	5500	NUM
dhrp-67	5	36	raphael	raphael	PROPN
dhrp-67	5	37	drive	drive	PROPN
dhrp-67	5	38	,	,	PUNCT
dhrp-67	5	39	edinburg	edinburg	PROPN
dhrp-67	5	40	,	,	PUNCT
dhrp-67	5	41	tx	tx	PROPN
dhrp-67	5	42	79539	79539	NUM
dhrp-67	5	43	orcid	orcid	NOUN
dhrp-67	5	44	:	:	PUNCT
dhrp-67	5	45	https://orcid.org/0000-0003-4146-3282	https://orcid.org/0000-0003-4146-3282	ADJ
dhrp-67	5	46	correspondence	correspondence	NOUN
dhrp-67	5	47	should	should	AUX
dhrp-67	5	48	be	be	AUX
dhrp-67	5	49	addressed	address	VERB
dhrp-67	5	50	to	to	ADP
dhrp-67	5	51	:	:	PUNCT
dhrp-67	5	52	sohail	sohail	PROPN
dhrp-67	5	53	rao	rao	PROPN
dhrp-67	5	54	,	,	PUNCT
dhrp-67	5	55	md	md	PROPN
dhrp-67	5	56	,	,	PUNCT
dhrp-67	5	57	ma	ma	PROPN
dhrp-67	5	58	,	,	PUNCT
dhrp-67	5	59	dphil	dphil	NOUN
dhrp-67	5	60	.	.	PUNCT
dhrp-67	5	61	,	,	PUNCT
dhrp-67	5	62	dhr	dhr	PROPN
dhrp-67	5	63	health	health	PROPN
dhrp-67	5	64	institute	institute	PROPN
dhrp-67	5	65	for	for	ADP
dhrp-67	5	66	research	research	PROPN
dhrp-67	5	67	&	&	CCONJ
dhrp-67	5	68	development	development	PROPN
dhrp-67	5	69	,	,	PUNCT
dhrp-67	5	70	5323	5323	NUM
dhrp-67	5	71	s.	s.	PROPN
dhrp-67	5	72	mccoll	mccoll	PROPN
dhrp-67	5	73	road	road	PROPN
dhrp-67	5	74	,	,	PUNCT
dhrp-67	5	75	edinburg	edinburg	PROPN
dhrp-67	5	76	,	,	PUNCT
dhrp-67	5	77	texas	texas	PROPN
dhrp-67	5	78	78539	78539	NUM
dhrp-67	5	79	.	.	PUNCT
dhrp-67	6	1	e	e	X
dhrp-67	6	2	-	-	NOUN
dhrp-67	6	3	mail	mail	NOUN
dhrp-67	6	4	:	:	PUNCT
dhrp-67	6	5	s.rao@dhr-rgv.com	s.rao@dhr-rgv.com	NOUN
dhrp-67	6	6	.	.	PUNCT
dhrp-67	7	1	keywords	keyword	NOUN
dhrp-67	7	2	:	:	PUNCT
dhrp-67	7	3	covid-19	covid-19	PROPN
dhrp-67	7	4	;	;	PUNCT
dhrp-67	7	5	sars	sar	NOUN
dhrp-67	7	6	-	-	PUNCT
dhrp-67	7	7	cov-2	cov-2	NUM
dhrp-67	7	8	;	;	PUNCT
dhrp-67	7	9	ba.5	ba.5	NOUN
dhrp-67	7	10	;	;	PUNCT
dhrp-67	7	11	ba.5	ba.5	PROPN
dhrp-67	7	12	;	;	PUNCT
dhrp-67	7	13	omicron	omicron	PROPN
dhrp-67	7	14	;	;	PUNCT
dhrp-67	7	15	paxlovid	paxlovid	PROPN
dhrp-67	7	16	;	;	PUNCT
dhrp-67	7	17	malnupiravir	malnupiravir	PROPN
dhrp-67	7	18	;	;	PUNCT
dhrp-67	7	19	bebtelovimab	bebtelovimab	NOUN
dhrp-67	7	20	;	;	PUNCT
dhrp-67	7	21	evusheldtm	evusheldtm	NUM
dhrp-67	7	22	;	;	PUNCT
dhrp-67	7	23	malnupiravir	malnupiravir	PROPN
dhrp-67	7	24	;	;	PUNCT
dhrp-67	7	25	remdesivir	remdesivir	PROPN
dhrp-67	7	26	;	;	PUNCT
dhrp-67	7	27	cdc	cdc	PROPN
dhrp-67	7	28	:	:	PUNCT
dhrp-67	7	29	centers	center	NOUN
dhrp-67	7	30	for	for	ADP
dhrp-67	7	31	disease	disease	NOUN
dhrp-67	7	32	control	control	NOUN
dhrp-67	7	33	and	and	CCONJ
dhrp-67	7	34	prevention	prevention	NOUN
dhrp-67	7	35	;	;	PUNCT
dhrp-67	7	36	fda	fda	PROPN
dhrp-67	7	37	:	:	PUNCT
dhrp-67	7	38	u.s	u.s	PROPN
dhrp-67	7	39	.	.	PROPN
dhrp-67	7	40	food	food	PROPN
dhrp-67	7	41	and	and	CCONJ
dhrp-67	7	42	drug	drug	NOUN
dhrp-67	7	43	administration	administration	NOUN
dhrp-67	7	44	;	;	PUNCT
dhrp-67	7	45	who	who	PRON
dhrp-67	7	46	:	:	PUNCT
dhrp-67	7	47	world	world	PROPN
dhrp-67	7	48	health	health	PROPN
dhrp-67	7	49	organization	organization	PROPN
dhrp-67	7	50	b.1.1.529	b.1.1.529	ADV
dhrp-67	7	51	,	,	PUNCT
dhrp-67	7	52	the	the	DET
dhrp-67	7	53	new	new	ADJ
dhrp-67	7	54	lineage	lineage	NOUN
dhrp-67	7	55	of	of	ADP
dhrp-67	7	56	sars	sar	NOUN
dhrp-67	7	57	-	-	PUNCT
dhrp-67	7	58	cov-2	cov-2	PART
dhrp-67	7	59	variant	variant	NOUN
dhrp-67	7	60	was	be	AUX
dhrp-67	7	61	first	first	ADV
dhrp-67	7	62	detected	detect	VERB
dhrp-67	7	63	in	in	ADP
dhrp-67	7	64	botswana	botswana	PROPN
dhrp-67	7	65	on	on	ADP
dhrp-67	7	66	november	november	PROPN
dhrp-67	7	67	11	11	NUM
dhrp-67	7	68	,	,	PUNCT
dhrp-67	7	69	2021	2021	NUM
dhrp-67	7	70	,	,	PUNCT
dhrp-67	7	71	and	and	CCONJ
dhrp-67	7	72	in	in	ADP
dhrp-67	7	73	south	south	PROPN
dhrp-67	7	74	africa	africa	PROPN
dhrp-67	7	75	on	on	ADP
dhrp-67	7	76	november	november	PROPN
dhrp-67	7	77	14	14	NUM
dhrp-67	7	78	,	,	PUNCT
dhrp-67	7	79	2021	2021	NUM
dhrp-67	7	80	.	.	PUNCT
dhrp-67	8	1	this	this	DET
dhrp-67	8	2	new	new	ADJ
dhrp-67	8	3	variant	variant	NOUN
dhrp-67	8	4	had	have	VERB
dhrp-67	8	5	many	many	ADJ
dhrp-67	8	6	mutations	mutation	NOUN
dhrp-67	8	7	in	in	ADP
dhrp-67	8	8	portions	portion	NOUN
dhrp-67	8	9	of	of	ADP
dhrp-67	8	10	the	the	DET
dhrp-67	8	11	genome	genome	NOUN
dhrp-67	8	12	that	that	PRON
dhrp-67	8	13	increased	increase	VERB
dhrp-67	8	14	its	its	PRON
dhrp-67	8	15	infectivity	infectivity	NOUN
dhrp-67	8	16	and	and	CCONJ
dhrp-67	8	17	transmissibility	transmissibility	NOUN
dhrp-67	8	18	;	;	PUNCT
dhrp-67	8	19	conferred	confer	VERB
dhrp-67	8	20	resistance	resistance	NOUN
dhrp-67	8	21	to	to	ADP
dhrp-67	8	22	certain	certain	ADJ
dhrp-67	8	23	therapeutics	therapeutic	NOUN
dhrp-67	8	24	;	;	PUNCT
dhrp-67	8	25	and	and	CCONJ
dhrp-67	8	26	reduced	reduce	VERB
dhrp-67	8	27	neutralization	neutralization	NOUN
dhrp-67	8	28	by	by	ADP
dhrp-67	8	29	monoclonal	monoclonal	NOUN
dhrp-67	8	30	antibodies	antibody	NOUN
dhrp-67	8	31	(	(	PUNCT
dhrp-67	8	32	1,2	1,2	NUM
dhrp-67	8	33	)	)	PUNCT
dhrp-67	8	34	.	.	PUNCT
dhrp-67	9	1	given	give	VERB
dhrp-67	9	2	these	these	DET
dhrp-67	9	3	observations	observation	NOUN
dhrp-67	9	4	,	,	PUNCT
dhrp-67	9	5	on	on	ADP
dhrp-67	9	6	november	november	PROPN
dhrp-67	9	7	26	26	NUM
dhrp-67	9	8	,	,	PUNCT
dhrp-67	9	9	2021	2021	NUM
dhrp-67	9	10	,	,	PUNCT
dhrp-67	9	11	who	who	PRON
dhrp-67	9	12	classified	classify	VERB
dhrp-67	9	13	b.1.1.529	b.1.1.529	ADV
dhrp-67	9	14	as	as	ADP
dhrp-67	9	15	a	a	DET
dhrp-67	9	16	variant	variant	NOUN
dhrp-67	9	17	of	of	ADP
dhrp-67	9	18	concern	concern	NOUN
dhrp-67	9	19	and	and	CCONJ
dhrp-67	9	20	named	name	VERB
dhrp-67	9	21	it	it	PRON
dhrp-67	9	22	omicron	omicron	NOUN
dhrp-67	9	23	(	(	PUNCT
dhrp-67	9	24	3	3	NUM
dhrp-67	9	25	)	)	PUNCT
dhrp-67	9	26	.	.	PUNCT
dhrp-67	10	1	on	on	ADP
dhrp-67	10	2	november	november	PROPN
dhrp-67	10	3	30	30	NUM
dhrp-67	10	4	,	,	PUNCT
dhrp-67	10	5	2021	2021	NUM
dhrp-67	10	6	,	,	PUNCT
dhrp-67	10	7	the	the	DET
dhrp-67	10	8	u.s	u.s	PROPN
dhrp-67	10	9	.	.	PROPN
dhrp-67	10	10	sarscov-2	sarscov-2	NUM
dhrp-67	10	11	interagency	interagency	NOUN
dhrp-67	10	12	group	group	NOUN
dhrp-67	10	13	(	(	PUNCT
dhrp-67	10	14	sig	sig	NOUN
dhrp-67	10	15	)	)	PUNCT
dhrp-67	10	16	,	,	PUNCT
dhrp-67	10	17	which	which	PRON
dhrp-67	10	18	includes	include	VERB
dhrp-67	10	19	the	the	DET
dhrp-67	10	20	centers	center	NOUN
dhrp-67	10	21	for	for	ADP
dhrp-67	10	22	disease	disease	NOUN
dhrp-67	10	23	control	control	NOUN
dhrp-67	10	24	and	and	CCONJ
dhrp-67	10	25	prevention	prevention	NOUN
dhrp-67	10	26	(	(	PUNCT
dhrp-67	10	27	cdc	cdc	PROPN
dhrp-67	10	28	)	)	PUNCT
dhrp-67	10	29	,	,	PUNCT
dhrp-67	10	30	the	the	DET
dhrp-67	10	31	national	national	PROPN
dhrp-67	10	32	institutes	institutes	PROPN
dhrp-67	10	33	of	of	ADP
dhrp-67	10	34	health	health	NOUN
dhrp-67	10	35	,	,	PUNCT
dhrp-67	10	36	the	the	DET
dhrp-67	10	37	food	food	NOUN
dhrp-67	10	38	and	and	CCONJ
dhrp-67	10	39	drug	drug	NOUN
dhrp-67	10	40	administration	administration	NOUN
dhrp-67	10	41	,	,	PUNCT
dhrp-67	10	42	the	the	DET
dhrp-67	10	43	biomedical	biomedical	ADJ
dhrp-67	10	44	advanced	advanced	ADJ
dhrp-67	10	45	research	research	NOUN
dhrp-67	10	46	and	and	CCONJ
dhrp-67	10	47	development	development	NOUN
dhrp-67	10	48	authority	authority	NOUN
dhrp-67	10	49	,	,	PUNCT
dhrp-67	10	50	and	and	CCONJ
dhrp-67	10	51	the	the	DET
dhrp-67	10	52	departments	department	NOUN
dhrp-67	10	53	of	of	ADP
dhrp-67	10	54	defense	defense	NOUN
dhrp-67	10	55	,	,	PUNCT
dhrp-67	10	56	agriculture	agriculture	NOUN
dhrp-67	10	57	,	,	PUNCT
dhrp-67	10	58	and	and	CCONJ
dhrp-67	10	59	health	health	NOUN
dhrp-67	10	60	and	and	CCONJ
dhrp-67	10	61	human	human	PROPN
dhrp-67	10	62	services	service	NOUN
dhrp-67	10	63	,	,	PUNCT
dhrp-67	10	64	classified	classify	VERB
dhrp-67	10	65	the	the	DET
dhrp-67	10	66	omicron	omicron	PROPN
dhrp-67	10	67	variant	variant	NOUN
dhrp-67	10	68	as	as	ADP
dhrp-67	10	69	a	a	DET
dhrp-67	10	70	variant	variant	NOUN
dhrp-67	10	71	of	of	ADP
dhrp-67	10	72	concern	concern	NOUN
dhrp-67	10	73	.	.	PUNCT
dhrp-67	11	1	since	since	SCONJ
dhrp-67	11	2	its	its	PRON
dhrp-67	11	3	first	first	ADJ
dhrp-67	11	4	identification	identification	NOUN
dhrp-67	11	5	,	,	PUNCT
dhrp-67	11	6	a	a	DET
dhrp-67	11	7	total	total	NOUN
dhrp-67	11	8	of	of	ADP
dhrp-67	11	9	six	six	NUM
dhrp-67	11	10	omicron	omicron	NOUN
dhrp-67	11	11	variants	variant	NOUN
dhrp-67	11	12	have	have	AUX
dhrp-67	11	13	been	be	AUX
dhrp-67	11	14	identified	identify	VERB
dhrp-67	11	15	(	(	PUNCT
dhrp-67	11	16	table	table	NOUN
dhrp-67	11	17	1	1	NUM
dhrp-67	11	18	)	)	PUNCT
dhrp-67	11	19	.	.	PUNCT
dhrp-67	12	1	many	many	ADJ
dhrp-67	12	2	of	of	ADP
dhrp-67	12	3	the	the	DET
dhrp-67	12	4	earlier	early	ADJ
dhrp-67	12	5	variants	variant	NOUN
dhrp-67	12	6	were	be	AUX
dhrp-67	12	7	responsive	responsive	ADJ
dhrp-67	12	8	to	to	PART
dhrp-67	12	9	available	available	VERB
dhrp-67	12	10	experimental	experimental	ADJ
dhrp-67	12	11	treatment	treatment	NOUN
dhrp-67	12	12	including	include	VERB
dhrp-67	12	13	monoclonal	monoclonal	NOUN
dhrp-67	12	14	antibodies	antibody	NOUN
dhrp-67	12	15	such	such	ADJ
dhrp-67	12	16	as	as	ADP
dhrp-67	12	17	sotrovimab	sotrovimab	NOUN
dhrp-67	12	18	(	(	PUNCT
dhrp-67	12	19	4	4	NUM
dhrp-67	12	20	)	)	PUNCT
dhrp-67	12	21	.	.	PUNCT
dhrp-67	13	1	however	however	ADV
dhrp-67	13	2	,	,	PUNCT
dhrp-67	13	3	both	both	DET
dhrp-67	13	4	ba.4	ba.4	PROPN
dhrp-67	13	5	and	and	CCONJ
dhrp-67	13	6	ba.5	ba.5	PROPN
dhrp-67	13	7	were	be	AUX
dhrp-67	13	8	found	find	VERB
dhrp-67	13	9	less	less	ADV
dhrp-67	13	10	responsive	responsive	ADJ
dhrp-67	13	11	to	to	ADP
dhrp-67	13	12	some	some	PRON
dhrp-67	13	13	for	for	ADP
dhrp-67	13	14	the	the	DET
dhrp-67	13	15	existing	exist	VERB
dhrp-67	13	16	therapies	therapy	NOUN
dhrp-67	13	17	.	.	PUNCT
dhrp-67	14	1	ba.4	ba.4	PROPN
dhrp-67	14	2	was	be	AUX
dhrp-67	14	3	first	first	ADV
dhrp-67	14	4	identified	identify	VERB
dhrp-67	14	5	in	in	ADP
dhrp-67	14	6	the	the	DET
dhrp-67	14	7	us	us	PROPN
dhrp-67	14	8	in	in	ADP
dhrp-67	14	9	april	april	PROPN
dhrp-67	14	10	2022	2022	NUM
dhrp-67	14	11	but	but	CCONJ
dhrp-67	14	12	was	be	AUX
dhrp-67	14	13	soon	soon	ADV
dhrp-67	14	14	replaced	replace	VERB
dhrp-67	14	15	by	by	ADP
dhrp-67	14	16	ba.5	ba.5	PROPN
dhrp-67	14	17	as	as	ADP
dhrp-67	14	18	the	the	DET
dhrp-67	14	19	dominant	dominant	ADJ
dhrp-67	14	20	variant	variant	NOUN
dhrp-67	14	21	that	that	PRON
dhrp-67	14	22	is	be	AUX
dhrp-67	14	23	currently	currently	ADV
dhrp-67	14	24	responsible	responsible	ADJ
dhrp-67	14	25	for	for	ADP
dhrp-67	14	26	majority	majority	NOUN
dhrp-67	14	27	of	of	ADP
dhrp-67	14	28	covid-19	covid-19	PROPN
dhrp-67	14	29	cases	case	NOUN
dhrp-67	14	30	https://orcid.org/0000-0001-5027-9992	https://orcid.org/0000-0001-5027-9992	PROPN
dhrp-67	14	31	https://orcid.org/0000-0003-4146-3282	https://orcid.org/0000-0003-4146-3282	PROPN
dhrp-67	14	32	mailto:s.rao@dhr-rgv.com	mailto:s.rao@dhr-rgv.com	PROPN
dhrp-67	14	33	rao	rao	PROPN
dhrp-67	14	34	,	,	PUNCT
dhrp-67	14	35	et	et	PROPN
dhrp-67	14	36	al	al	PROPN
dhrp-67	14	37	paxlovid	paxlovid	PROPN
dhrp-67	14	38	rebound	rebound	VERB
dhrp-67	14	39	https://doi.org/10.47488/dhrp.v2is3.67	https://doi.org/10.47488/dhrp.v2is3.67	PROPN
dhrp-67	14	40	dhr	dhr	PROPN
dhrp-67	14	41	proceedings	proceeding	NOUN
dhrp-67	14	42	ǀ	ǀ	ADP
dhrp-67	14	43	http://dhrproceedings.org	http://dhrproceedings.org	PROPN
dhrp-67	14	44	2022	2022	NUM
dhrp-67	14	45	,	,	PUNCT
dhrp-67	14	46	vol	vol	NOUN
dhrp-67	14	47	.	.	NOUN
dhrp-67	14	48	2	2	NUM
dhrp-67	15	1	no	no	NOUN
dhrp-67	15	2	.	.	PUNCT
dhrp-67	16	1	s3	s3	PROPN
dhrp-67	16	2	1	1	NUM
dhrp-67	16	3	-	-	SYM
dhrp-67	16	4	9	9	NUM
dhrp-67	16	5	2	2	NUM
dhrp-67	16	6	(	(	PUNCT
dhrp-67	16	7	figure	figure	NOUN
dhrp-67	16	8	1	1	NUM
dhrp-67	16	9	)	)	PUNCT
dhrp-67	16	10	.	.	PUNCT
dhrp-67	17	1	ba.5	ba.5	PROPN
dhrp-67	17	2	is	be	AUX
dhrp-67	17	3	probably	probably	ADV
dhrp-67	17	4	the	the	DET
dhrp-67	17	5	most	most	ADV
dhrp-67	17	6	transmissible	transmissible	ADJ
dhrp-67	17	7	variant	variant	NOUN
dhrp-67	17	8	of	of	ADP
dhrp-67	17	9	omicron	omicron	PROPN
dhrp-67	17	10	and	and	CCONJ
dhrp-67	17	11	has	have	VERB
dhrp-67	17	12	certain	certain	ADJ
dhrp-67	17	13	characteristic	characteristic	NOUN
dhrp-67	17	14	that	that	PRON
dhrp-67	17	15	are	be	AUX
dhrp-67	17	16	unique	unique	ADJ
dhrp-67	17	17	to	to	ADP
dhrp-67	17	18	this	this	DET
dhrp-67	17	19	mutant	mutant	NOUN
dhrp-67	17	20	:	:	PUNCT
dhrp-67	17	21	•	•	NUM
dhrp-67	17	22	infects	infect	VERB
dhrp-67	17	23	those	those	PRON
dhrp-67	17	24	who	who	PRON
dhrp-67	17	25	have	have	AUX
dhrp-67	17	26	had	have	VERB
dhrp-67	17	27	previous	previous	ADJ
dhrp-67	17	28	natural	natural	ADJ
dhrp-67	17	29	infection	infection	NOUN
dhrp-67	17	30	from	from	ADP
dhrp-67	17	31	earlier	early	ADJ
dhrp-67	17	32	variants	variant	NOUN
dhrp-67	17	33	of	of	ADP
dhrp-67	17	34	sars	sars	PROPN
dhrp-67	17	35	-	-	PUNCT
dhrp-67	17	36	cov2	cov2	PROPN
dhrp-67	17	37	•	•	ADV
dhrp-67	17	38	escapes	escape	VERB
dhrp-67	17	39	immunity	immunity	NOUN
dhrp-67	17	40	due	due	ADP
dhrp-67	17	41	to	to	ADP
dhrp-67	17	42	covid-19	covid-19	PROPN
dhrp-67	17	43	vaccination	vaccination	NOUN
dhrp-67	17	44	•	•	ADP
dhrp-67	17	45	poor	poor	ADJ
dhrp-67	17	46	neutralization	neutralization	NOUN
dhrp-67	17	47	by	by	ADP
dhrp-67	17	48	previously	previously	ADV
dhrp-67	17	49	existing	exist	VERB
dhrp-67	17	50	experimental	experimental	ADJ
dhrp-67	17	51	monoclonal	monoclonal	NOUN
dhrp-67	17	52	antibodies	antibody	NOUN
dhrp-67	17	53	given	give	VERB
dhrp-67	17	54	these	these	DET
dhrp-67	17	55	characteristics	characteristic	NOUN
dhrp-67	17	56	,	,	PUNCT
dhrp-67	17	57	fda	fda	PROPN
dhrp-67	17	58	revised	revise	VERB
dhrp-67	17	59	its	its	PRON
dhrp-67	17	60	recommendation	recommendation	NOUN
dhrp-67	17	61	for	for	ADP
dhrp-67	17	62	the	the	DET
dhrp-67	17	63	treatment	treatment	NOUN
dhrp-67	17	64	of	of	ADP
dhrp-67	17	65	hospitalized	hospitalize	VERB
dhrp-67	17	66	and	and	CCONJ
dhrp-67	17	67	nonhospitalized	nonhospitalize	VERB
dhrp-67	17	68	patients	patient	NOUN
dhrp-67	17	69	infected	infect	VERB
dhrp-67	17	70	with	with	ADP
dhrp-67	17	71	the	the	DET
dhrp-67	17	72	ba.4	ba.4	PROPN
dhrp-67	17	73	and	and	CCONJ
dhrp-67	17	74	ba.5	ba.5	PROPN
dhrp-67	17	75	variants	variant	NOUN
dhrp-67	17	76	of	of	ADP
dhrp-67	17	77	omicron	omicron	PROPN
dhrp-67	17	78	(	(	PUNCT
dhrp-67	17	79	table	table	NOUN
dhrp-67	17	80	2	2	NUM
dhrp-67	17	81	)	)	PUNCT
dhrp-67	17	82	.	.	PUNCT
dhrp-67	18	1	paxlovid	paxlovid	PROPN
dhrp-67	18	2	,	,	PUNCT
dhrp-67	18	3	an	an	DET
dhrp-67	18	4	oral	oral	ADJ
dhrp-67	18	5	antiviral	antiviral	ADJ
dhrp-67	18	6	medication	medication	NOUN
dhrp-67	18	7	,	,	PUNCT
dhrp-67	18	8	was	be	AUX
dhrp-67	18	9	recommended	recommend	VERB
dhrp-67	18	10	as	as	ADP
dhrp-67	18	11	the	the	DET
dhrp-67	18	12	preferred	preferred	ADJ
dhrp-67	18	13	option	option	NOUN
dhrp-67	18	14	for	for	ADP
dhrp-67	18	15	the	the	DET
dhrp-67	18	16	treatment	treatment	NOUN
dhrp-67	18	17	of	of	ADP
dhrp-67	18	18	nonhospitalized	nonhospitalize	VERB
dhrp-67	18	19	mild	mild	ADJ
dhrp-67	18	20	-	-	PUNCT
dhrp-67	18	21	to	to	ADP
dhrp-67	18	22	-	-	PUNCT
dhrp-67	18	23	moderate	moderate	ADJ
dhrp-67	18	24	sars	sar	NOUN
dhrp-67	18	25	-	-	PUNCT
dhrp-67	18	26	cov-2	cov-2	NOUN
dhrp-67	18	27	infection	infection	NOUN
dhrp-67	18	28	in	in	ADP
dhrp-67	18	29	individuals	individual	NOUN
dhrp-67	18	30	12	12	NUM
dhrp-67	18	31	and	and	CCONJ
dhrp-67	18	32	older	old	ADJ
dhrp-67	18	33	at	at	ADP
dhrp-67	18	34	high	high	ADJ
dhrp-67	18	35	risk	risk	NOUN
dhrp-67	18	36	of	of	ADP
dhrp-67	18	37	progression	progression	NOUN
dhrp-67	18	38	to	to	ADP
dhrp-67	18	39	severe	severe	ADJ
dhrp-67	18	40	disease	disease	NOUN
dhrp-67	18	41	(	(	PUNCT
dhrp-67	18	42	figure	figure	NOUN
dhrp-67	18	43	3	3	NUM
dhrp-67	18	44	and	and	CCONJ
dhrp-67	18	45	4	4	NUM
dhrp-67	18	46	)	)	PUNCT
dhrp-67	18	47	.	.	PUNCT
dhrp-67	19	1	additionally	additionally	ADV
dhrp-67	19	2	,	,	PUNCT
dhrp-67	19	3	bebtelovimab	bebtelovimab	NOUN
dhrp-67	19	4	,	,	PUNCT
dhrp-67	19	5	a	a	DET
dhrp-67	19	6	monoclonal	monoclonal	NOUN
dhrp-67	19	7	antibody	antibody	NOUN
dhrp-67	19	8	for	for	ADP
dhrp-67	19	9	the	the	DET
dhrp-67	19	10	treatment	treatment	NOUN
dhrp-67	19	11	of	of	ADP
dhrp-67	19	12	acute	acute	NOUN
dhrp-67	19	13	covid-19	covid-19	PROPN
dhrp-67	19	14	in	in	ADP
dhrp-67	19	15	the	the	DET
dhrp-67	19	16	outpatient	outpatient	NOUN
dhrp-67	19	17	setting	setting	NOUN
dhrp-67	19	18	,	,	PUNCT
dhrp-67	19	19	is	be	AUX
dhrp-67	19	20	equally	equally	ADV
dhrp-67	19	21	effective	effective	ADJ
dhrp-67	19	22	but	but	CCONJ
dhrp-67	19	23	in	in	ADP
dhrp-67	19	24	extremely	extremely	ADV
dhrp-67	19	25	short	short	ADJ
dhrp-67	19	26	supply	supply	NOUN
dhrp-67	19	27	and	and	CCONJ
dhrp-67	19	28	it	it	PRON
dhrp-67	19	29	is	be	AUX
dhrp-67	19	30	recommended	recommend	VERB
dhrp-67	19	31	that	that	SCONJ
dhrp-67	19	32	it	it	PRON
dhrp-67	19	33	should	should	AUX
dhrp-67	19	34	be	be	AUX
dhrp-67	19	35	reserved	reserve	VERB
dhrp-67	19	36	for	for	ADP
dhrp-67	19	37	individuals	individual	NOUN
dhrp-67	19	38	with	with	ADP
dhrp-67	19	39	a	a	DET
dhrp-67	19	40	contraindication	contraindication	NOUN
dhrp-67	19	41	to	to	ADP
dhrp-67	19	42	preferred	preferred	ADJ
dhrp-67	19	43	therapies	therapy	NOUN
dhrp-67	19	44	.	.	PUNCT
dhrp-67	20	1	more	more	ADV
dhrp-67	20	2	importantly	importantly	ADV
dhrp-67	20	3	,	,	PUNCT
dhrp-67	20	4	availability	availability	NOUN
dhrp-67	20	5	of	of	ADP
dhrp-67	20	6	bebtelovimab	bebtelovimab	NOUN
dhrp-67	20	7	after	after	ADP
dhrp-67	20	8	the	the	DET
dhrp-67	20	9	third	third	ADJ
dhrp-67	20	10	week	week	NOUN
dhrp-67	20	11	of	of	ADP
dhrp-67	20	12	august	august	PROPN
dhrp-67	20	13	is	be	AUX
dhrp-67	20	14	uncertain	uncertain	ADJ
dhrp-67	20	15	and	and	CCONJ
dhrp-67	20	16	as	as	ADP
dhrp-67	20	17	of	of	ADP
dhrp-67	20	18	august	august	PROPN
dhrp-67	20	19	01	01	NUM
dhrp-67	20	20	,	,	PUNCT
dhrp-67	20	21	2022	2022	NUM
dhrp-67	20	22	,	,	PUNCT
dhrp-67	20	23	patients	patient	NOUN
dhrp-67	20	24	would	would	AUX
dhrp-67	20	25	be	be	AUX
dhrp-67	20	26	required	require	VERB
dhrp-67	20	27	to	to	PART
dhrp-67	20	28	pay	pay	VERB
dhrp-67	20	29	to	to	PART
dhrp-67	20	30	get	get	AUX
dhrp-67	20	31	treated	treat	VERB
dhrp-67	20	32	with	with	ADP
dhrp-67	20	33	this	this	DET
dhrp-67	20	34	monoclonal	monoclonal	NOUN
dhrp-67	20	35	antibody	antibody	NOUN
dhrp-67	20	36	.	.	PUNCT
dhrp-67	21	1	it	it	PRON
dhrp-67	21	2	is	be	AUX
dhrp-67	21	3	noteworthy	noteworthy	ADJ
dhrp-67	21	4	that	that	SCONJ
dhrp-67	21	5	under	under	ADP
dhrp-67	21	6	an	an	DET
dhrp-67	21	7	irb	irb	NOUN
dhrp-67	21	8	-	-	PUNCT
dhrp-67	21	9	approved	approve	VERB
dhrp-67	21	10	protocol	protocol	NOUN
dhrp-67	21	11	,	,	PUNCT
dhrp-67	21	12	we	we	PRON
dhrp-67	21	13	at	at	ADP
dhrp-67	21	14	the	the	DET
dhrp-67	21	15	dhr	dhr	PROPN
dhrp-67	21	16	health	health	PROPN
dhrp-67	21	17	institute	institute	PROPN
dhrp-67	21	18	for	for	ADP
dhrp-67	21	19	research	research	PROPN
dhrp-67	21	20	&	&	CCONJ
dhrp-67	21	21	development	development	PROPN
dhrp-67	21	22	have	have	AUX
dhrp-67	21	23	treated	treat	VERB
dhrp-67	21	24	to	to	ADP
dhrp-67	21	25	date	date	NOUN
dhrp-67	21	26	over	over	ADP
dhrp-67	21	27	400	400	NUM
dhrp-67	21	28	high	high	ADJ
dhrp-67	21	29	risk	risk	NOUN
dhrp-67	21	30	covid-19	covid-19	PROPN
dhrp-67	21	31	positive	positive	ADJ
dhrp-67	21	32	patients	patient	NOUN
dhrp-67	21	33	with	with	ADP
dhrp-67	21	34	bebtelovimab	bebtelovimab	NOUN
dhrp-67	21	35	with	with	ADP
dhrp-67	21	36	very	very	ADV
dhrp-67	21	37	satisfactory	satisfactory	ADJ
dhrp-67	21	38	outcomes	outcome	NOUN
dhrp-67	21	39	.	.	PUNCT
dhrp-67	22	1	while	while	SCONJ
dhrp-67	22	2	paxlovid	paxlovid	PROPN
dhrp-67	22	3	is	be	AUX
dhrp-67	22	4	the	the	DET
dhrp-67	22	5	recommended	recommend	VERB
dhrp-67	22	6	drug	drug	NOUN
dhrp-67	22	7	of	of	ADP
dhrp-67	22	8	choice	choice	NOUN
dhrp-67	22	9	for	for	ADP
dhrp-67	22	10	treating	treat	VERB
dhrp-67	22	11	mild	mild	ADJ
dhrp-67	22	12	-	-	PUNCT
dhrp-67	22	13	moderate	moderate	ADJ
dhrp-67	22	14	nonhospitalized	nonhospitalize	VERB
dhrp-67	22	15	patients	patient	NOUN
dhrp-67	22	16	,	,	PUNCT
dhrp-67	22	17	it	it	PRON
dhrp-67	22	18	does	do	AUX
dhrp-67	22	19	have	have	VERB
dhrp-67	22	20	certain	certain	ADJ
dhrp-67	22	21	limitations	limitation	NOUN
dhrp-67	22	22	(	(	PUNCT
dhrp-67	22	23	5	5	NUM
dhrp-67	22	24	)	)	PUNCT
dhrp-67	22	25	.	.	PUNCT
dhrp-67	23	1	despite	despite	SCONJ
dhrp-67	23	2	its	its	PRON
dhrp-67	23	3	therapeutic	therapeutic	ADJ
dhrp-67	23	4	effectiveness	effectiveness	NOUN
dhrp-67	23	5	,	,	PUNCT
dhrp-67	23	6	paxlovid	paxlovid	PROPN
dhrp-67	23	7	is	be	AUX
dhrp-67	23	8	contraindicated	contraindicate	VERB
dhrp-67	23	9	in	in	ADP
dhrp-67	23	10	the	the	DET
dhrp-67	23	11	following	follow	VERB
dhrp-67	23	12	conditions	condition	NOUN
dhrp-67	23	13	which	which	PRON
dhrp-67	23	14	limits	limit	VERB
dhrp-67	23	15	its	its	PRON
dhrp-67	23	16	utility	utility	NOUN
dhrp-67	23	17	(	(	PUNCT
dhrp-67	23	18	6	6	NUM
dhrp-67	23	19	):	):	PUNCT
dhrp-67	23	20	•	•	NUM
dhrp-67	23	21	patients	patient	NOUN
dhrp-67	23	22	requiring	require	VERB
dhrp-67	23	23	hospitalization	hospitalization	NOUN
dhrp-67	23	24	•	•	ADP
dhrp-67	23	25	for	for	ADP
dhrp-67	23	26	pre	pre	ADJ
dhrp-67	23	27	-	-	NOUN
dhrp-67	23	28	exposure	exposure	ADJ
dhrp-67	23	29	or	or	CCONJ
dhrp-67	23	30	post	post	ADJ
dhrp-67	23	31	-	-	ADJ
dhrp-67	23	32	exposure	exposure	ADJ
dhrp-67	23	33	prophylaxis	prophylaxis	NOUN
dhrp-67	23	34	•	•	NOUN
dhrp-67	23	35	for	for	ADP
dhrp-67	23	36	use	use	NOUN
dhrp-67	23	37	beyond	beyond	ADP
dhrp-67	23	38	recommended	recommend	VERB
dhrp-67	23	39	5	5	NUM
dhrp-67	23	40	consecutive	consecutive	ADJ
dhrp-67	23	41	days	day	NOUN
dhrp-67	23	42	•	•	ADP
dhrp-67	23	43	patients	patient	NOUN
dhrp-67	23	44	with	with	ADP
dhrp-67	23	45	clinically	clinically	ADV
dhrp-67	23	46	significant	significant	ADJ
dhrp-67	23	47	hypersensitivity	hypersensitivity	NOUN
dhrp-67	23	48	reactions	reaction	NOUN
dhrp-67	23	49	(	(	PUNCT
dhrp-67	23	50	e.g.	e.g.	ADV
dhrp-67	23	51	,	,	PUNCT
dhrp-67	23	52	toxic	toxic	ADJ
dhrp-67	23	53	epidermal	epidermal	ADJ
dhrp-67	23	54	necrolysis	necrolysis	NOUN
dhrp-67	23	55	and	and	CCONJ
dhrp-67	23	56	stevens	stevens	PROPN
dhrp-67	23	57	-	-	PUNCT
dhrp-67	23	58	johnson	johnson	PROPN
dhrp-67	23	59	syndrome	syndrome	PROPN
dhrp-67	23	60	)	)	PUNCT
dhrp-67	23	61	•	•	ADP
dhrp-67	23	62	patients	patient	NOUN
dhrp-67	23	63	on	on	ADP
dhrp-67	23	64	drugs	drug	NOUN
dhrp-67	23	65	requiring	require	VERB
dhrp-67	23	66	cyp3a	cyp3a	NOUN
dhrp-67	23	67	for	for	ADP
dhrp-67	23	68	clearance	clearance	NOUN
dhrp-67	23	69	•	•	NUM
dhrp-67	23	70	patients	patient	NOUN
dhrp-67	23	71	on	on	ADP
dhrp-67	23	72	drugs	drug	NOUN
dhrp-67	23	73	that	that	PRON
dhrp-67	23	74	are	be	AUX
dhrp-67	23	75	potent	potent	ADJ
dhrp-67	23	76	induces	induce	NOUN
dhrp-67	23	77	of	of	ADP
dhrp-67	23	78	cyp3a	cyp3a	NOUN
dhrp-67	23	79	of	of	ADP
dhrp-67	23	80	equal	equal	ADJ
dhrp-67	23	81	concern	concern	NOUN
dhrp-67	23	82	is	be	AUX
dhrp-67	23	83	the	the	DET
dhrp-67	23	84	recent	recent	ADJ
dhrp-67	23	85	observation	observation	NOUN
dhrp-67	23	86	of	of	ADP
dhrp-67	23	87	high	high	ADJ
dhrp-67	23	88	incidence	incidence	NOUN
dhrp-67	23	89	of	of	ADP
dhrp-67	23	90	re	re	NOUN
dhrp-67	23	91	-	-	NOUN
dhrp-67	23	92	infection	infection	NOUN
dhrp-67	23	93	following	follow	VERB
dhrp-67	23	94	treatment	treatment	NOUN
dhrp-67	23	95	with	with	ADP
dhrp-67	23	96	paxlovid	paxlovid	PROPN
dhrp-67	23	97	(	(	PUNCT
dhrp-67	23	98	8)	8)	NUM
dhrp-67	23	99	.	.	PUNCT
dhrp-67	24	1	in	in	ADP
dhrp-67	24	2	a	a	DET
dhrp-67	24	3	recent	recent	ADJ
dhrp-67	24	4	study	study	NOUN
dhrp-67	24	5	involving	involve	VERB
dhrp-67	24	6	13,600	13,600	NUM
dhrp-67	24	7	patients	patient	NOUN
dhrp-67	24	8	,	,	PUNCT
dhrp-67	24	9	it	it	PRON
dhrp-67	24	10	was	be	AUX
dhrp-67	24	11	reported	report	VERB
dhrp-67	24	12	that	that	SCONJ
dhrp-67	24	13	7	7	NUM
dhrp-67	24	14	-	-	PUNCT
dhrp-67	24	15	day	day	NOUN
dhrp-67	24	16	and	and	CCONJ
dhrp-67	24	17	30	30	NUM
dhrp-67	24	18	-	-	PUNCT
dhrp-67	24	19	day	day	NOUN
dhrp-67	24	20	covid-19	covid-19	PROPN
dhrp-67	24	21	rebound	rebound	NOUN
dhrp-67	24	22	rates	rate	NOUN
dhrp-67	24	23	after	after	SCONJ
dhrp-67	24	24	paxlovid	paxlovid	PROPN
dhrp-67	24	25	treatment	treatment	NOUN
dhrp-67	24	26	were	be	AUX
dhrp-67	24	27	3.53	3.53	NUM
dhrp-67	24	28	%	%	NOUN
dhrp-67	24	29	and	and	CCONJ
dhrp-67	24	30	5.40	5.40	NUM
dhrp-67	24	31	%	%	NOUN
dhrp-67	24	32	for	for	ADP
dhrp-67	24	33	sars	sar	NOUN
dhrp-67	24	34	-	-	PUNCT
dhrp-67	24	35	cov-2	cov-2	PART
dhrp-67	24	36	infection	infection	NOUN
dhrp-67	24	37	,	,	PUNCT
dhrp-67	24	38	2.31	2.31	NUM
dhrp-67	24	39	%	%	NOUN
dhrp-67	24	40	and	and	CCONJ
dhrp-67	24	41	5.87	5.87	NUM
dhrp-67	24	42	%	%	NOUN
dhrp-67	24	43	for	for	ADP
dhrp-67	24	44	covid-19	covid-19	PROPN
dhrp-67	24	45	symptoms	symptom	NOUN
dhrp-67	24	46	,	,	PUNCT
dhrp-67	24	47	and	and	CCONJ
dhrp-67	24	48	0.44	0.44	NUM
dhrp-67	24	49	%	%	NOUN
dhrp-67	24	50	and	and	CCONJ
dhrp-67	24	51	0.77	0.77	NUM
dhrp-67	24	52	%	%	NOUN
dhrp-67	24	53	for	for	ADP
dhrp-67	24	54	hospitalizations	hospitalization	NOUN
dhrp-67	24	55	(	(	PUNCT
dhrp-67	24	56	8)	8)	NUM
dhrp-67	24	57	.	.	PUNCT
dhrp-67	25	1	while	while	SCONJ
dhrp-67	25	2	it	it	PRON
dhrp-67	25	3	requires	require	VERB
dhrp-67	25	4	further	further	ADJ
dhrp-67	25	5	validation	validation	NOUN
dhrp-67	25	6	,	,	PUNCT
dhrp-67	25	7	there	there	PRON
dhrp-67	25	8	is	be	VERB
dhrp-67	25	9	however	however	ADV
dhrp-67	25	10	some	some	DET
dhrp-67	25	11	recent	recent	ADJ
dhrp-67	25	12	evidence	evidence	NOUN
dhrp-67	25	13	that	that	SCONJ
dhrp-67	25	14	the	the	DET
dhrp-67	25	15	re	re	NOUN
dhrp-67	25	16	-	-	NOUN
dhrp-67	25	17	infection	infection	NOUN
dhrp-67	25	18	rate	rate	NOUN
dhrp-67	25	19	is	be	AUX
dhrp-67	25	20	probably	probably	ADV
dhrp-67	25	21	as	as	ADV
dhrp-67	25	22	high	high	ADJ
dhrp-67	25	23	as	as	ADP
dhrp-67	25	24	20	20	NUM
dhrp-67	25	25	-	-	SYM
dhrp-67	25	26	40	40	NUM
dhrp-67	25	27	%	%	NOUN
dhrp-67	25	28	in	in	ADP
dhrp-67	25	29	patients	patient	NOUN
dhrp-67	25	30	treated	treat	VERB
dhrp-67	25	31	with	with	ADP
dhrp-67	25	32	paxlovid	paxlovid	PROPN
dhrp-67	25	33	(	(	PUNCT
dhrp-67	25	34	9	9	NUM
dhrp-67	25	35	)	)	PUNCT
dhrp-67	25	36	.	.	PUNCT
dhrp-67	26	1	rebound	rebound	NOUN
dhrp-67	26	2	of	of	ADP
dhrp-67	26	3	sars	sar	NOUN
dhrp-67	26	4	-	-	PUNCT
dhrp-67	26	5	cov-2	cov-2	NOUN
dhrp-67	26	6	infection	infection	NOUN
dhrp-67	26	7	in	in	ADP
dhrp-67	26	8	high	high	ADJ
dhrp-67	26	9	profile	profile	NOUN
dhrp-67	26	10	cases	case	NOUN
dhrp-67	26	11	following	follow	VERB
dhrp-67	26	12	the	the	DET
dhrp-67	26	13	recommended	recommend	VERB
dhrp-67	26	14	5	5	NUM
dhrp-67	26	15	-	-	PUNCT
dhrp-67	26	16	day	day	NOUN
dhrp-67	26	17	oral	oral	ADJ
dhrp-67	26	18	treatment	treatment	NOUN
dhrp-67	26	19	with	with	ADP
dhrp-67	26	20	paxlovid	paxlovid	PROPN
dhrp-67	26	21	has	have	AUX
dhrp-67	26	22	further	far	ADV
dhrp-67	26	23	highlighted	highlight	VERB
dhrp-67	26	24	this	this	DET
dhrp-67	26	25	concern	concern	NOUN
dhrp-67	26	26	(	(	PUNCT
dhrp-67	26	27	10	10	NUM
dhrp-67	26	28	11	11	NUM
dhrp-67	26	29	)	)	PUNCT
dhrp-67	26	30	.	.	PUNCT
dhrp-67	27	1	in	in	ADP
dhrp-67	27	2	one	one	NUM
dhrp-67	27	3	particular	particular	ADJ
dhrp-67	27	4	case	case	NOUN
dhrp-67	27	5	,	,	PUNCT
dhrp-67	27	6	the	the	DET
dhrp-67	27	7	patient	patient	NOUN
dhrp-67	27	8	resorted	resort	VERB
dhrp-67	27	9	to	to	ADP
dhrp-67	27	10	taking	take	VERB
dhrp-67	27	11	a	a	DET
dhrp-67	27	12	second	second	ADJ
dhrp-67	27	13	course	course	NOUN
dhrp-67	27	14	of	of	ADP
dhrp-67	27	15	paxlovid	paxlovid	PROPN
dhrp-67	27	16	after	after	ADP
dhrp-67	27	17	experiencing	experience	VERB
dhrp-67	27	18	covid-19	covid-19	PROPN
dhrp-67	27	19	rebound	rebound	VERB
dhrp-67	27	20	which	which	PRON
dhrp-67	27	21	,	,	PUNCT
dhrp-67	27	22	at	at	ADP
dhrp-67	27	23	the	the	DET
dhrp-67	27	24	present	present	ADJ
dhrp-67	27	25	time	time	NOUN
dhrp-67	27	26	is	be	AUX
dhrp-67	27	27	not	not	PART
dhrp-67	27	28	recommended	recommend	VERB
dhrp-67	27	29	by	by	ADP
dhrp-67	27	30	the	the	DET
dhrp-67	27	31	fda	fda	PROPN
dhrp-67	27	32	(	(	PUNCT
dhrp-67	27	33	10	10	NUM
dhrp-67	27	34	)	)	PUNCT
dhrp-67	27	35	.	.	PUNCT
dhrp-67	28	1	rebound	rebound	NOUN
dhrp-67	28	2	of	of	ADP
dhrp-67	28	3	covid-19	covid-19	PROPN
dhrp-67	28	4	symptoms	symptom	NOUN
dhrp-67	28	5	following	follow	VERB
dhrp-67	28	6	the	the	DET
dhrp-67	28	7	use	use	NOUN
dhrp-67	28	8	of	of	ADP
dhrp-67	28	9	paxlovid	paxlovid	PROPN
dhrp-67	28	10	treatment	treatment	NOUN
dhrp-67	28	11	is	be	AUX
dhrp-67	28	12	likely	likely	ADJ
dhrp-67	28	13	due	due	ADJ
dhrp-67	28	14	to	to	ADP
dhrp-67	28	15	insufficient	insufficient	ADJ
dhrp-67	28	16	drug	drug	NOUN
dhrp-67	28	17	exposure	exposure	NOUN
dhrp-67	28	18	:	:	PUNCT
dhrp-67	28	19	not	not	PART
dhrp-67	28	20	enough	enough	ADJ
dhrp-67	28	21	of	of	ADP
dhrp-67	28	22	the	the	DET
dhrp-67	28	23	drug	drug	NOUN
dhrp-67	28	24	was	be	AUX
dhrp-67	28	25	getting	get	VERB
dhrp-67	28	26	to	to	ADP
dhrp-67	28	27	infected	infected	ADJ
dhrp-67	28	28	cells	cell	NOUN
dhrp-67	28	29	to	to	PART
dhrp-67	28	30	stop	stop	VERB
dhrp-67	28	31	all	all	DET
dhrp-67	28	32	viral	viral	ADJ
dhrp-67	28	33	replication	replication	NOUN
dhrp-67	28	34	.	.	PUNCT
dhrp-67	29	1	this	this	PRON
dhrp-67	29	2	could	could	AUX
dhrp-67	29	3	be	be	AUX
dhrp-67	29	4	due	due	ADJ
dhrp-67	29	5	to	to	ADP
dhrp-67	29	6	the	the	DET
dhrp-67	29	7	drug	drug	NOUN
dhrp-67	29	8	being	be	AUX
dhrp-67	29	9	rao	rao	NOUN
dhrp-67	29	10	,	,	PUNCT
dhrp-67	29	11	et	et	PROPN
dhrp-67	29	12	al	al	PROPN
dhrp-67	29	13	paxlovid	paxlovid	PROPN
dhrp-67	29	14	rebound	rebound	VERB
dhrp-67	29	15	https://doi.org/10.47488/dhrp.v2is3.67	https://doi.org/10.47488/dhrp.v2is3.67	PROPN
dhrp-67	29	16	dhr	dhr	PROPN
dhrp-67	29	17	proceedings	proceeding	NOUN
dhrp-67	29	18	ǀ	ǀ	ADP
dhrp-67	29	19	http://dhrproceedings.org	http://dhrproceedings.org	PROPN
dhrp-67	29	20	2022	2022	NUM
dhrp-67	29	21	,	,	PUNCT
dhrp-67	29	22	vol	vol	NOUN
dhrp-67	29	23	.	.	NOUN
dhrp-67	29	24	2	2	NUM
dhrp-67	30	1	no	no	NOUN
dhrp-67	30	2	.	.	PUNCT
dhrp-67	31	1	s3	s3	PROPN
dhrp-67	31	2	1	1	NUM
dhrp-67	31	3	-	-	SYM
dhrp-67	31	4	9	9	NUM
dhrp-67	31	5	3	3	NUM
dhrp-67	31	6	metabolized	metabolize	VERB
dhrp-67	31	7	more	more	ADV
dhrp-67	31	8	quickly	quickly	ADV
dhrp-67	31	9	in	in	ADP
dhrp-67	31	10	some	some	DET
dhrp-67	31	11	individuals	individual	NOUN
dhrp-67	31	12	or	or	CCONJ
dhrp-67	31	13	that	that	SCONJ
dhrp-67	31	14	the	the	DET
dhrp-67	31	15	drug	drug	NOUN
dhrp-67	31	16	needs	need	VERB
dhrp-67	31	17	to	to	PART
dhrp-67	31	18	be	be	AUX
dhrp-67	31	19	delivered	deliver	VERB
dhrp-67	31	20	over	over	ADP
dhrp-67	31	21	a	a	DET
dhrp-67	31	22	longer	long	ADJ
dhrp-67	31	23	treatment	treatment	NOUN
dhrp-67	31	24	duration	duration	NOUN
dhrp-67	31	25	.	.	PUNCT
dhrp-67	32	1	it	it	PRON
dhrp-67	32	2	is	be	AUX
dhrp-67	32	3	therefore	therefore	ADV
dhrp-67	32	4	our	our	PRON
dhrp-67	32	5	recommendation	recommendation	NOUN
dhrp-67	32	6	that	that	PRON
dhrp-67	32	7	has	have	AUX
dhrp-67	32	8	also	also	ADV
dhrp-67	32	9	been	be	AUX
dhrp-67	32	10	voiced	voice	VERB
dhrp-67	32	11	by	by	ADP
dhrp-67	32	12	others	other	NOUN
dhrp-67	32	13	(	(	PUNCT
dhrp-67	32	14	12	12	NUM
dhrp-67	32	15	)	)	PUNCT
dhrp-67	32	16	that	that	SCONJ
dhrp-67	32	17	both	both	DET
dhrp-67	32	18	pfizer	pfizer	NOUN
dhrp-67	32	19	(	(	PUNCT
dhrp-67	32	20	the	the	DET
dhrp-67	32	21	manufactures	manufacture	NOUN
dhrp-67	32	22	of	of	ADP
dhrp-67	32	23	paxlovid	paxlovid	PROPN
dhrp-67	32	24	)	)	PUNCT
dhrp-67	32	25	and	and	CCONJ
dhrp-67	32	26	fda	fda	PROPN
dhrp-67	32	27	review	review	VERB
dhrp-67	32	28	the	the	DET
dhrp-67	32	29	data	datum	NOUN
dhrp-67	32	30	and	and	CCONJ
dhrp-67	32	31	either	either	CCONJ
dhrp-67	32	32	increase	increase	VERB
dhrp-67	32	33	the	the	DET
dhrp-67	32	34	duration	duration	NOUN
dhrp-67	32	35	of	of	ADP
dhrp-67	32	36	treatment	treatment	NOUN
dhrp-67	32	37	(	(	PUNCT
dhrp-67	32	38	from	from	ADP
dhrp-67	32	39	5	5	NUM
dhrp-67	32	40	days	day	NOUN
dhrp-67	32	41	to	to	ADP
dhrp-67	32	42	7	7	NUM
dhrp-67	32	43	-	-	SYM
dhrp-67	32	44	10	10	NUM
dhrp-67	32	45	days	day	NOUN
dhrp-67	32	46	)	)	PUNCT
dhrp-67	32	47	and/or	and/or	CCONJ
dhrp-67	32	48	allow	allow	VERB
dhrp-67	32	49	the	the	DET
dhrp-67	32	50	use	use	NOUN
dhrp-67	32	51	of	of	ADP
dhrp-67	32	52	another	another	DET
dhrp-67	32	53	3–5	3–5	NUM
dhrp-67	32	54	-	-	PUNCT
dhrp-67	32	55	day	day	NOUN
dhrp-67	32	56	course	course	NOUN
dhrp-67	32	57	of	of	ADP
dhrp-67	32	58	paxlovid	paxlovid	PROPN
dhrp-67	32	59	for	for	ADP
dhrp-67	32	60	patients	patient	NOUN
dhrp-67	32	61	suffering	suffer	VERB
dhrp-67	32	62	from	from	ADP
dhrp-67	32	63	rebound	rebound	NOUN
dhrp-67	32	64	.	.	PUNCT
dhrp-67	33	1	alternatively	alternatively	ADV
dhrp-67	33	2	combined	combine	VERB
dhrp-67	33	3	use	use	NOUN
dhrp-67	33	4	of	of	ADP
dhrp-67	33	5	bebtelovimab	bebtelovimab	NOUN
dhrp-67	33	6	and	and	CCONJ
dhrp-67	33	7	paxlovid	paxlovid	PROPN
dhrp-67	33	8	could	could	AUX
dhrp-67	33	9	be	be	AUX
dhrp-67	33	10	considered	consider	VERB
dhrp-67	33	11	for	for	ADP
dhrp-67	33	12	contemporaneous	contemporaneous	ADJ
dhrp-67	33	13	reduction	reduction	NOUN
dhrp-67	33	14	of	of	ADP
dhrp-67	33	15	both	both	CCONJ
dhrp-67	33	16	the	the	DET
dhrp-67	33	17	circulating	circulate	VERB
dhrp-67	33	18	viral	viral	ADJ
dhrp-67	33	19	load	load	NOUN
dhrp-67	33	20	and	and	CCONJ
dhrp-67	33	21	prevention	prevention	NOUN
dhrp-67	33	22	of	of	ADP
dhrp-67	33	23	viral	viral	ADJ
dhrp-67	33	24	replication	replication	NOUN
dhrp-67	33	25	in	in	ADP
dhrp-67	33	26	infected	infected	ADJ
dhrp-67	33	27	cells	cell	NOUN
dhrp-67	33	28	.	.	PUNCT
dhrp-67	34	1	funding	funding	NOUN
dhrp-67	34	2	:	:	PUNCT
dhrp-67	34	3	the	the	DET
dhrp-67	34	4	project	project	NOUN
dhrp-67	34	5	was	be	AUX
dhrp-67	34	6	funded	fund	VERB
dhrp-67	34	7	by	by	ADP
dhrp-67	34	8	a	a	DET
dhrp-67	34	9	seed	seed	NOUN
dhrp-67	34	10	grant	grant	NOUN
dhrp-67	34	11	from	from	ADP
dhrp-67	34	12	the	the	DET
dhrp-67	34	13	dhr	dhr	PROPN
dhrp-67	34	14	health	health	PROPN
dhrp-67	34	15	institute	institute	PROPN
dhrp-67	34	16	for	for	ADP
dhrp-67	34	17	research	research	PROPN
dhrp-67	34	18	&	&	CCONJ
dhrp-67	34	19	development	development	PROPN
dhrp-67	34	20	and	and	CCONJ
dhrp-67	34	21	the	the	DET
dhrp-67	34	22	dhr	dhr	PROPN
dhrp-67	34	23	health	health	PROPN
dhrp-67	34	24	conflict	conflict	NOUN
dhrp-67	34	25	of	of	ADP
dhrp-67	34	26	interest	interest	NOUN
dhrp-67	34	27	:	:	PUNCT
dhrp-67	34	28	the	the	DET
dhrp-67	34	29	authors	author	NOUN
dhrp-67	34	30	have	have	AUX
dhrp-67	34	31	reported	report	VERB
dhrp-67	34	32	no	no	DET
dhrp-67	34	33	conflict	conflict	NOUN
dhrp-67	34	34	of	of	ADP
dhrp-67	34	35	interest	interest	NOUN
dhrp-67	34	36	references	reference	NOUN
dhrp-67	34	37	:	:	PUNCT
dhrp-67	35	1	1	1	X
dhrp-67	35	2	.	.	X
dhrp-67	36	1	chen	chen	PROPN
dhrp-67	36	2	j	j	PROPN
dhrp-67	36	3	,	,	PUNCT
dhrp-67	36	4	wei	wei	PROPN
dhrp-67	36	5	gw	gw	PROPN
dhrp-67	36	6	.	.	PUNCT
dhrp-67	37	1	omicron	omicron	PROPN
dhrp-67	37	2	ba.2	ba.2	PROPN
dhrp-67	37	3	(	(	PUNCT
dhrp-67	37	4	b.1.1.529.2	b.1.1.529.2	NOUN
dhrp-67	37	5	):	):	PUNCT
dhrp-67	37	6	high	high	ADJ
dhrp-67	37	7	potential	potential	NOUN
dhrp-67	37	8	to	to	ADP
dhrp-67	37	9	becoming	become	VERB
dhrp-67	37	10	the	the	DET
dhrp-67	37	11	next	next	ADJ
dhrp-67	37	12	dominating	dominating	NOUN
dhrp-67	37	13	variant	variant	NOUN
dhrp-67	37	14	.	.	PUNCT
dhrp-67	38	1	res	re	NOUN
dhrp-67	38	2	sq	sq	PROPN
dhrp-67	39	1	[	[	X
dhrp-67	39	2	preprint	preprint	NOUN
dhrp-67	39	3	]	]	X
dhrp-67	39	4	.	.	PUNCT
dhrp-67	40	1	2022	2022	NUM
dhrp-67	40	2	feb	feb	NOUN
dhrp-67	40	3	23	23	NUM
dhrp-67	40	4	:	:	PUNCT
dhrp-67	40	5	rs.3.rs-1362445	rs.3.rs-1362445	NOUN
dhrp-67	40	6	.	.	PUNCT
dhrp-67	41	1	doi	doi	NOUN
dhrp-67	41	2	:	:	PUNCT
dhrp-67	41	3	10.21203	10.21203	NUM
dhrp-67	41	4	/	/	SYM
dhrp-67	41	5	rs.3.rs-1362445	rs.3.rs-1362445	NOUN
dhrp-67	41	6	/	/	SYM
dhrp-67	41	7	v1	v1	NOUN
dhrp-67	41	8	.	.	PUNCT
dhrp-67	42	1	update	update	NOUN
dhrp-67	42	2	in	in	ADP
dhrp-67	42	3	:	:	PUNCT
dhrp-67	42	4	j	j	PROPN
dhrp-67	42	5	phys	phy	NOUN
dhrp-67	42	6	chem	chem	NOUN
dhrp-67	42	7	lett	lett	PROPN
dhrp-67	42	8	.	.	PUNCT
dhrp-67	43	1	2022	2022	NUM
dhrp-67	43	2	apr	apr	VERB
dhrp-67	43	3	25:3840	25:3840	NUM
dhrp-67	43	4	-	-	SYM
dhrp-67	43	5	3849	3849	NUM
dhrp-67	43	6	.	.	PUNCT
dhrp-67	44	1	pmid	pmid	NOUN
dhrp-67	44	2	:	:	PUNCT
dhrp-67	44	3	35233567	35233567	NUM
dhrp-67	44	4	;	;	PUNCT
dhrp-67	44	5	pmcid	pmcid	NOUN
dhrp-67	44	6	:	:	PUNCT
dhrp-67	44	7	pmc8887081	pmc8887081	ADJ
dhrp-67	44	8	.	.	PUNCT
dhrp-67	45	1	2	2	X
dhrp-67	45	2	.	.	X
dhrp-67	45	3	chen	chen	PROPN
dhrp-67	45	4	j	j	PROPN
dhrp-67	45	5	,	,	PUNCT
dhrp-67	45	6	wang	wang	PROPN
dhrp-67	45	7	r	r	PROPN
dhrp-67	45	8	,	,	PUNCT
dhrp-67	45	9	gilby	gilby	PROPN
dhrp-67	45	10	nb	nb	PROPN
dhrp-67	45	11	,	,	PUNCT
dhrp-67	45	12	wei	wei	PROPN
dhrp-67	45	13	gw	gw	PROPN
dhrp-67	45	14	.	.	PUNCT
dhrp-67	46	1	omicron	omicron	PROPN
dhrp-67	46	2	variant	variant	NOUN
dhrp-67	46	3	(	(	PUNCT
dhrp-67	46	4	b.1.1.529	b.1.1.529	ADV
dhrp-67	46	5	):	):	PUNCT
dhrp-67	46	6	infectivity	infectivity	NOUN
dhrp-67	46	7	,	,	PUNCT
dhrp-67	46	8	vaccine	vaccine	NOUN
dhrp-67	46	9	breakthrough	breakthrough	NOUN
dhrp-67	46	10	,	,	PUNCT
dhrp-67	46	11	and	and	CCONJ
dhrp-67	46	12	antibody	antibody	NOUN
dhrp-67	46	13	resistance	resistance	NOUN
dhrp-67	46	14	.	.	PUNCT
dhrp-67	47	1	j	j	PROPN
dhrp-67	47	2	chem	chem	PROPN
dhrp-67	47	3	inf	inf	PROPN
dhrp-67	47	4	model	model	NOUN
dhrp-67	47	5	.	.	PUNCT
dhrp-67	48	1	2022	2022	NUM
dhrp-67	48	2	jan	jan	PROPN
dhrp-67	48	3	24;62(2):412	24;62(2):412	NUM
dhrp-67	48	4	-	-	PUNCT
dhrp-67	48	5	422	422	NUM
dhrp-67	48	6	.	.	PUNCT
dhrp-67	49	1	doi	doi	NOUN
dhrp-67	49	2	:	:	PUNCT
dhrp-67	49	3	10.1021	10.1021	NUM
dhrp-67	49	4	/	/	SYM
dhrp-67	49	5	acs.jcim.1c01451	acs.jcim.1c01451	PROPN
dhrp-67	49	6	.	.	PUNCT
dhrp-67	50	1	epub	epub	NOUN
dhrp-67	50	2	2022	2022	NUM
dhrp-67	50	3	jan	jan	PROPN
dhrp-67	50	4	6	6	NUM
dhrp-67	50	5	.	.	PUNCT
dhrp-67	50	6	pmid	pmid	NOUN
dhrp-67	50	7	:	:	PUNCT
dhrp-67	50	8	34989238	34989238	NUM
dhrp-67	50	9	;	;	PUNCT
dhrp-67	50	10	pmcid	pmcid	ADJ
dhrp-67	50	11	:	:	PUNCT
dhrp-67	50	12	pmc8751645	pmc8751645	ADJ
dhrp-67	50	13	.	.	PUNCT
dhrp-67	51	1	3	3	X
dhrp-67	51	2	.	.	X
dhrp-67	51	3	classification	classification	NOUN
dhrp-67	51	4	of	of	ADP
dhrp-67	51	5	omicron	omicron	PROPN
dhrp-67	51	6	(	(	PUNCT
dhrp-67	51	7	b.1.1.529	b.1.1.529	ADV
dhrp-67	51	8	):	):	PUNCT
dhrp-67	51	9	sars	sar	NOUN
dhrp-67	51	10	-	-	PUNCT
dhrp-67	51	11	cov-2	cov-2	NOUN
dhrp-67	51	12	variant	variant	NOUN
dhrp-67	51	13	of	of	ADP
dhrp-67	51	14	concern	concern	NOUN
dhrp-67	51	15	.	.	PUNCT
dhrp-67	52	1	who	who	PRON
dhrp-67	52	2	.	.	PUNCT
dhrp-67	53	1	november	november	PROPN
dhrp-67	53	2	26	26	NUM
dhrp-67	53	3	,	,	PUNCT
dhrp-67	53	4	2021	2021	NUM
dhrp-67	53	5	.	.	PUNCT
dhrp-67	54	1	https://www.who.int/news/item/26-11-2021classification-of-omicron-(b.1.1.529)-sarscov-2-variant-of-concern	https://www.who.int/news/item/26-11-2021classification-of-omicron-(b.1.1.529)-sarscov-2-variant-of-concern	PROPN
dhrp-67	54	2	4	4	NUM
dhrp-67	54	3	.	.	PUNCT
dhrp-67	54	4	martin	martin	NOUN
dhrp-67	54	5	-	-	PUNCT
dhrp-67	54	6	blondel	blondel	NOUN
dhrp-67	54	7	g	g	PROPN
dhrp-67	54	8	,	,	PUNCT
dhrp-67	54	9	marcelin	marcelin	PROPN
dhrp-67	54	10	ag	ag	PROPN
dhrp-67	54	11	,	,	PUNCT
dhrp-67	54	12	soulié	soulié	NOUN
dhrp-67	54	13	c	c	PROPN
dhrp-67	54	14	,	,	PUNCT
dhrp-67	54	15	et.al	et.al	PROPN
dhrp-67	54	16	.	.	PUNCT
dhrp-67	55	1	sotrovimab	sotrovimab	NOUN
dhrp-67	55	2	to	to	PART
dhrp-67	55	3	prevent	prevent	VERB
dhrp-67	55	4	severe	severe	ADJ
dhrp-67	55	5	covid19	covid19	NOUN
dhrp-67	55	6	in	in	ADP
dhrp-67	55	7	high	high	ADJ
dhrp-67	55	8	-	-	PUNCT
dhrp-67	55	9	risk	risk	NOUN
dhrp-67	55	10	patients	patient	NOUN
dhrp-67	55	11	infected	infect	VERB
dhrp-67	55	12	with	with	ADP
dhrp-67	55	13	omicron	omicron	PROPN
dhrp-67	55	14	ba.2	ba.2	PROPN
dhrp-67	55	15	.	.	PUNCT
dhrp-67	56	1	j	j	PROPN
dhrp-67	56	2	infect	infect	VERB
dhrp-67	56	3	.	.	PUNCT
dhrp-67	57	1	2022	2022	NUM
dhrp-67	57	2	jul	jul	NOUN
dhrp-67	57	3	5	5	NUM
dhrp-67	57	4	:	:	PUNCT
dhrp-67	57	5	s01634453(22)00406	s01634453(22)00406	PROPN
dhrp-67	57	6	-	-	PUNCT
dhrp-67	57	7	6	6	NUM
dhrp-67	57	8	.	.	PUNCT
dhrp-67	57	9	doi	doi	NOUN
dhrp-67	57	10	:	:	PUNCT
dhrp-67	57	11	10.1016	10.1016	NUM
dhrp-67	57	12	/	/	SYM
dhrp-67	57	13	j.jinf.2022.06.033	j.jinf.2022.06.033	PROPN
dhrp-67	57	14	.	.	PUNCT
dhrp-67	58	1	epub	epub	NOUN
dhrp-67	58	2	ahead	ahead	ADV
dhrp-67	58	3	of	of	ADP
dhrp-67	58	4	print	print	NOUN
dhrp-67	58	5	.	.	PUNCT
dhrp-67	59	1	pmid	pmid	NOUN
dhrp-67	59	2	:	:	PUNCT
dhrp-67	59	3	35803386	35803386	NUM
dhrp-67	59	4	;	;	PUNCT
dhrp-67	59	5	pmcid	pmcid	ADJ
dhrp-67	59	6	:	:	PUNCT
dhrp-67	59	7	pmc9254651	pmc9254651	ADJ
dhrp-67	59	8	.	.	PUNCT
dhrp-67	60	1	5	5	X
dhrp-67	60	2	.	.	X
dhrp-67	60	3	hammond	hammond	PROPN
dhrp-67	60	4	,	,	PUNCT
dhrp-67	60	5	j.	j.	PROPN
dhrp-67	60	6	,	,	PUNCT
dhrp-67	60	7	leister	leister	NOUN
dhrp-67	60	8	-	-	PUNCT
dhrp-67	60	9	tebbe	tebbe	NOUN
dhrp-67	60	10	,	,	PUNCT
dhrp-67	60	11	h.	h.	PROPN
dhrp-67	60	12	,	,	PUNCT
dhrp-67	60	13	gardner	gardner	PROPN
dhrp-67	60	14	,	,	PUNCT
dhrp-67	60	15	a	a	DET
dhrp-67	60	16	,	,	PUNCT
dhrp-67	60	17	et.al	et.al	PROPN
dhrp-67	60	18	.	.	PUNCT
dhrp-67	61	1	oral	oral	ADJ
dhrp-67	61	2	nirmatrelvir	nirmatrelvir	PROPN
dhrp-67	61	3	for	for	ADP
dhrp-67	61	4	high	high	ADJ
dhrp-67	61	5	-	-	PUNCT
dhrp-67	61	6	risk	risk	NOUN
dhrp-67	61	7	,	,	PUNCT
dhrp-67	61	8	nonhospitalized	nonhospitalize	VERB
dhrp-67	61	9	adults	adult	NOUN
dhrp-67	61	10	with	with	ADP
dhrp-67	61	11	covid19.hammond	covid19.hammond	NOUN
dhrp-67	61	12	,	,	PUNCT
dhrp-67	61	13	ph.d	ph.d	PROPN
dhrp-67	61	14	.	.	PROPN
dhrp-67	61	15	,	,	PUNCT
dhrp-67	61	16	april	april	PROPN
dhrp-67	61	17	14	14	NUM
dhrp-67	61	18	,	,	PUNCT
dhrp-67	61	19	2022	2022	NUM
dhrp-67	61	20	n	n	PRON
dhrp-67	61	21	engl	engl	PROPN
dhrp-67	61	22	j	j	PROPN
dhrp-67	61	23	med	med	PROPN
dhrp-67	61	24	2022	2022	NUM
dhrp-67	61	25	;	;	PUNCT
dhrp-67	61	26	386:1397	386:1397	NUM
dhrp-67	61	27	-	-	SYM
dhrp-67	61	28	1408	1408	NUM
dhrp-67	61	29	doi	doi	NOUN
dhrp-67	61	30	:	:	PUNCT
dhrp-67	61	31	10.1056	10.1056	NUM
dhrp-67	61	32	/	/	SYM
dhrp-67	61	33	nejmoa2118542	nejmoa2118542	NOUN
dhrp-67	61	34	6	6	NUM
dhrp-67	61	35	.	.	PUNCT
dhrp-67	62	1	coronavirus	coronavirus	NOUN
dhrp-67	62	2	(	(	PUNCT
dhrp-67	62	3	covid-19	covid-19	PROPN
dhrp-67	62	4	)	)	PUNCT
dhrp-67	62	5	update	update	NOUN
dhrp-67	62	6	:	:	PUNCT
dhrp-67	62	7	fda	fda	PROPN
dhrp-67	62	8	authorizes	authorize	VERB
dhrp-67	62	9	first	first	ADJ
dhrp-67	62	10	oral	oral	ADJ
dhrp-67	62	11	antiviral	antiviral	NOUN
dhrp-67	62	12	for	for	ADP
dhrp-67	62	13	treatment	treatment	NOUN
dhrp-67	62	14	of	of	ADP
dhrp-67	62	15	covid-19	covid-19	PROPN
dhrp-67	62	16	.	.	PUNCT
dhrp-67	63	1	fda	fda	PROPN
dhrp-67	63	2	.	.	PUNCT
dhrp-67	64	1	december	december	PROPN
dhrp-67	64	2	22	22	NUM
dhrp-67	64	3	,	,	PUNCT
dhrp-67	64	4	2021	2021	NUM
dhrp-67	64	5	.	.	PUNCT
dhrp-67	65	1	https://www.fda.gov/news-events/pressannouncements/coronavirus-covid-19update-fda-authorizes-first-oral-antiviraltreatment-covid-19	https://www.fda.gov/news-events/pressannouncements/coronavirus-covid-19update-fda-authorizes-first-oral-antiviraltreatment-covid-19	PROPN
dhrp-67	65	2	7	7	NUM
dhrp-67	65	3	.	.	PUNCT
dhrp-67	66	1	covid-19	covid-19	PROPN
dhrp-67	66	2	rebound	rebound	VERB
dhrp-67	66	3	after	after	ADP
dhrp-67	66	4	paxlovid	paxlovid	PROPN
dhrp-67	66	5	treatment	treatment	NOUN
dhrp-67	66	6	.	.	PUNCT
dhrp-67	67	1	cdc	cdc	PROPN
dhrp-67	67	2	.	.	PUNCT
dhrp-67	68	1	may	may	AUX
dhrp-67	68	2	24	24	NUM
dhrp-67	68	3	,	,	PUNCT
dhrp-67	68	4	2022	2022	NUM
dhrp-67	68	5	,	,	PUNCT
dhrp-67	68	6	https://emergency.cdc.gov/han/2022/han004	https://emergency.cdc.gov/han/2022/han004	PROPN
dhrp-67	68	7	67.asp	67.asp	PROPN
dhrp-67	68	8	8	8	NUM
dhrp-67	68	9	.	.	PUNCT
dhrp-67	69	1	wang	wang	PROPN
dhrp-67	69	2	l.	l.	PROPN
dhrp-67	69	3	,	,	PUNCT
dhrp-67	69	4	berger	berger	PROPN
dhrp-67	69	5	na	na	PROPN
dhrp-67	69	6	.	.	PROPN
dhrp-67	69	7	,	,	PUNCT
dhrp-67	69	8	davis	davis	PROPN
dhrp-67	69	9	pb	pb	PROPN
dhrp-67	69	10	.	.	PROPN
dhrp-67	69	11	,	,	PUNCT
dhrp-67	69	12	et.al	et.al	PROPN
dhrp-67	69	13	.	.	PUNCT
dhrp-67	70	1	covid19	covid19	PROPN
dhrp-67	70	2	rebound	rebound	VERB
dhrp-67	70	3	after	after	ADP
dhrp-67	70	4	paxlovid	paxlovid	PROPN
dhrp-67	70	5	and	and	CCONJ
dhrp-67	70	6	molnupiravir	molnupiravir	PROPN
dhrp-67	70	7	during	during	ADP
dhrp-67	70	8	january	january	PROPN
dhrp-67	70	9	-	-	PUNCT
dhrp-67	70	10	june	june	PROPN
dhrp-67	70	11	2022	2022	NUM
dhrp-67	70	12	,	,	PUNCT
dhrp-67	70	13	medrxiv	medrxiv	NOUN
dhrp-67	70	14	2022	2022	NUM
dhrp-67	70	15	.	.	PUNCT
dhrp-67	71	1	08.21.22276724	08.21.22276724	NOUN
dhrp-67	71	2	;	;	PUNCT
dhrp-67	71	3	https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern	https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern	PROPN
dhrp-67	71	4	https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern	https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern	PROPN
dhrp-67	71	5	https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern	https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern	PROPN
dhrp-67	71	6	https://www.nejm.org/doi/full/10.1056/nejmoa2118542	https://www.nejm.org/doi/full/10.1056/nejmoa2118542	PROPN
dhrp-67	71	7	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19	PROPN
dhrp-67	71	8	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19	PROPN
dhrp-67	71	9	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19	PROPN
dhrp-67	71	10	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19	PROPN
dhrp-67	71	11	https://emergency.cdc.gov/han/2022/han00467.asp	https://emergency.cdc.gov/han/2022/han00467.asp	PROPN
dhrp-67	71	12	https://emergency.cdc.gov/han/2022/han00467.asp	https://emergency.cdc.gov/han/2022/han00467.asp	PROPN
dhrp-67	71	13	rao	rao	PROPN
dhrp-67	71	14	,	,	PUNCT
dhrp-67	71	15	et	et	PROPN
dhrp-67	71	16	al	al	PROPN
dhrp-67	71	17	paxlovid	paxlovid	PROPN
dhrp-67	71	18	rebound	rebound	VERB
dhrp-67	71	19	https://doi.org/10.47488/dhrp.v2is3.67	https://doi.org/10.47488/dhrp.v2is3.67	PROPN
dhrp-67	71	20	dhr	dhr	PROPN
dhrp-67	71	21	proceedings	proceeding	NOUN
dhrp-67	71	22	ǀ	ǀ	ADP
dhrp-67	71	23	http://dhrproceedings.org	http://dhrproceedings.org	PROPN
dhrp-67	71	24	2022	2022	NUM
dhrp-67	71	25	,	,	PUNCT
dhrp-67	71	26	vol	vol	NOUN
dhrp-67	71	27	.	.	NOUN
dhrp-67	71	28	2	2	NUM
dhrp-67	72	1	no	no	NOUN
dhrp-67	72	2	.	.	PUNCT
dhrp-67	73	1	s3	s3	PROPN
dhrp-67	73	2	1	1	NUM
dhrp-67	73	3	-	-	SYM
dhrp-67	73	4	9	9	NUM
dhrp-67	73	5	4	4	NUM
dhrp-67	73	6	doi	doi	NOUN
dhrp-67	73	7	:	:	PUNCT
dhrp-67	73	8	https://doi.org/10.1101/2022.06.21.222	https://doi.org/10.1101/2022.06.21.222	NOUN
dhrp-67	73	9	76724	76724	NUM
dhrp-67	73	10	9	9	NUM
dhrp-67	73	11	.	.	PUNCT
dhrp-67	74	1	farrell	farrell	PROPN
dhrp-67	74	2	p.	p.	PROPN
dhrp-67	74	3	covid	covid	PROPN
dhrp-67	74	4	reinfection	reinfection	NOUN
dhrp-67	74	5	rate	rate	NOUN
dhrp-67	74	6	with	with	ADP
dhrp-67	74	7	treatment	treatment	NOUN
dhrp-67	74	8	biden	biden	PROPN
dhrp-67	74	9	is	be	AUX
dhrp-67	74	10	taking	take	VERB
dhrp-67	74	11	is	be	AUX
dhrp-67	74	12	more	more	ADJ
dhrp-67	74	13	than	than	ADP
dhrp-67	74	14	40	40	NUM
dhrp-67	74	15	%	%	NOUN
dhrp-67	74	16	and	and	CCONJ
dhrp-67	74	17	not	not	PART
dhrp-67	74	18	2	2	NUM
dhrp-67	74	19	%	%	NOUN
dhrp-67	74	20	as	as	SCONJ
dhrp-67	74	21	marketed	market	VERB
dhrp-67	74	22	:	:	PUNCT
dhrp-67	74	23	paxlovid	paxlovid	PROPN
dhrp-67	74	24	is	be	AUX
dhrp-67	74	25	thought	think	VERB
dhrp-67	74	26	to	to	PART
dhrp-67	74	27	suppress	suppress	VERB
dhrp-67	74	28	immune	immune	ADJ
dhrp-67	74	29	response	response	NOUN
dhrp-67	74	30	meaning	mean	VERB
dhrp-67	74	31	body	body	NOUN
dhrp-67	74	32	ca	can	AUX
dhrp-67	74	33	n’t	not	PART
dhrp-67	74	34	fight	fight	VERB
dhrp-67	74	35	off	off	ADP
dhrp-67	74	36	new	new	ADJ
dhrp-67	74	37	infection	infection	NOUN
dhrp-67	74	38	.	.	PUNCT
dhrp-67	75	1	daily	daily	ADJ
dhrp-67	75	2	mail	mail	NOUN
dhrp-67	75	3	.	.	PUNCT
dhrp-67	76	1	july	july	PROPN
dhrp-67	76	2	30	30	NUM
dhrp-67	76	3	,	,	PUNCT
dhrp-67	76	4	2022	2022	NUM
dhrp-67	76	5	.	.	PUNCT
dhrp-67	77	1	https://www.dailymail.co.uk/news/article11065467/covid-reinfection-rate-treatmentbiden-taking-40-not-2-marketed.html	https://www.dailymail.co.uk/news/article11065467/covid-reinfection-rate-treatmentbiden-taking-40-not-2-marketed.html	PROPN
dhrp-67	77	2	10	10	NUM
dhrp-67	77	3	.	.	PUNCT
dhrp-67	78	1	lee	lee	PROPN
dhrp-67	78	2	by	by	ADP
dhrp-67	78	3	.	.	PUNCT
dhrp-67	79	1	dr	dr	PROPN
dhrp-67	79	2	.	.	PROPN
dhrp-67	79	3	fauci	fauci	PROPN
dhrp-67	79	4	takes	take	VERB
dhrp-67	79	5	2nd	2nd	ADJ
dhrp-67	79	6	course	course	NOUN
dhrp-67	79	7	of	of	ADP
dhrp-67	79	8	paxlovid	paxlovid	PROPN
dhrp-67	79	9	after	after	ADP
dhrp-67	79	10	suffering	suffer	VERB
dhrp-67	79	11	covid-19	covid-19	PROPN
dhrp-67	79	12	rebound	rebound	NOUN
dhrp-67	79	13	.	.	PUNCT
dhrp-67	80	1	forbes	forbes	PROPN
dhrp-67	80	2	.	.	PROPN
dhrp-67	81	1	june	june	PROPN
dhrp-67	81	2	30	30	NUM
dhrp-67	81	3	,	,	PUNCT
dhrp-67	81	4	2022	2022	NUM
dhrp-67	81	5	.	.	PUNCT
dhrp-67	82	1	https://www.forbes.com/sites/brucelee/2022/	https://www.forbes.com/sites/brucelee/2022/	NOUN
dhrp-67	82	2	06/30	06/30	PROPN
dhrp-67	82	3	/	/	SYM
dhrp-67	82	4	dr	dr	NOUN
dhrp-67	82	5	-	-	PUNCT
dhrp-67	82	6	fauci	fauci	ADJ
dhrp-67	82	7	-	-	PUNCT
dhrp-67	82	8	takes-2nd	takes-2nd	NOUN
dhrp-67	82	9	-	-	PUNCT
dhrp-67	82	10	course	course	NOUN
dhrp-67	82	11	-	-	PUNCT
dhrp-67	82	12	ofpaxlovid	ofpaxlovid	NOUN
dhrp-67	82	13	-	-	PUNCT
dhrp-67	82	14	after	after	ADP
dhrp-67	82	15	-	-	PUNCT
dhrp-67	82	16	suffering	suffering	NOUN
dhrp-67	82	17	-	-	PUNCT
dhrp-67	82	18	covid-19rebound/?sh=4964bf0315d6	covid-19rebound/?sh=4964bf0315d6	NOUN
dhrp-67	82	19	11	11	NUM
dhrp-67	82	20	.	.	PUNCT
dhrp-67	83	1	judd	judd	PROPN
dhrp-67	83	2	d	d	PROPN
dhrp-67	83	3	and	and	CCONJ
dhrp-67	83	4	cole	cole	PROPN
dhrp-67	83	5	d.	d.	PROPN
dhrp-67	83	6	biden	biden	PROPN
dhrp-67	83	7	still	still	ADV
dhrp-67	83	8	testing	test	VERB
dhrp-67	83	9	positive	positive	ADJ
dhrp-67	83	10	after	after	ADP
dhrp-67	83	11	rebound	rebound	NOUN
dhrp-67	83	12	covid-19	covid-19	PROPN
dhrp-67	83	13	case	case	NOUN
dhrp-67	83	14	but	but	CCONJ
dhrp-67	83	15	‘	'	PUNCT
dhrp-67	83	16	continues	continue	VERB
dhrp-67	83	17	to	to	PART
dhrp-67	83	18	feel	feel	VERB
dhrp-67	83	19	well	well	ADV
dhrp-67	83	20	,	,	PUNCT
dhrp-67	83	21	’	'	PUNCT
dhrp-67	83	22	white	white	PROPN
dhrp-67	83	23	house	house	PROPN
dhrp-67	83	24	says	say	VERB
dhrp-67	83	25	.	.	PUNCT
dhrp-67	84	1	cnn	cnn	PROPN
dhrp-67	84	2	.	.	PUNCT
dhrp-67	85	1	july	july	PROPN
dhrp-67	85	2	31	31	NUM
dhrp-67	85	3	,	,	PUNCT
dhrp-67	85	4	2022	2022	NUM
dhrp-67	85	5	.	.	PUNCT
dhrp-67	86	1	https://www.cnn.com/2022/07/31/politics/jo	https://www.cnn.com/2022/07/31/politics/jo	PROPN
dhrp-67	86	2	e	e	X
dhrp-67	86	3	-	-	NOUN
dhrp-67	86	4	biden	biden	ADJ
dhrp-67	86	5	-	-	PUNCT
dhrp-67	86	6	covid	covid	VERB
dhrp-67	86	7	-	-	PUNCT
dhrp-67	86	8	positive	positive	ADJ
dhrp-67	86	9	-	-	PUNCT
dhrp-67	86	10	day	day	NOUN
dhrp-67	86	11	-	-	PUNCT
dhrp-67	86	12	two	two	NUM
dhrp-67	86	13	/	/	SYM
dhrp-67	86	14	index.html	index.html	PROPN
dhrp-67	86	15	12	12	NUM
dhrp-67	86	16	.	.	PUNCT
dhrp-67	86	17	mlynark	mlynark	PROPN
dhrp-67	86	18	n.	n.	PROPN
dhrp-67	86	19	covid-19	covid-19	PROPN
dhrp-67	86	20	rebound	rebound	VERB
dhrp-67	86	21	after	after	ADP
dhrp-67	86	22	taking	take	VERB
dhrp-67	86	23	paxlovid	paxlovid	PROPN
dhrp-67	86	24	likely	likely	ADJ
dhrp-67	86	25	due	due	ADP
dhrp-67	86	26	to	to	ADP
dhrp-67	86	27	insufficient	insufficient	ADJ
dhrp-67	86	28	drug	drug	NOUN
dhrp-67	86	29	exposure	exposure	NOUN
dhrp-67	86	30	.	.	PUNCT
dhrp-67	87	1	ucsd	ucsd	PROPN
dhrp-67	87	2	.	.	PROPN
dhrp-67	88	1	june	june	PROPN
dhrp-67	88	2	21	21	NUM
dhrp-67	88	3	,	,	PUNCT
dhrp-67	88	4	2022	2022	NUM
dhrp-67	88	5	.	.	PUNCT
dhrp-67	89	1	https://health.ucsd.edu/news/releases/pages/	https://health.ucsd.edu/news/releases/pages/	NOUN
dhrp-67	89	2	2022	2022	NUM
dhrp-67	89	3	-	-	SYM
dhrp-67	89	4	06	06	NUM
dhrp-67	89	5	-	-	PUNCT
dhrp-67	89	6	21	21	NUM
dhrp-67	89	7	-	-	PUNCT
dhrp-67	89	8	covid-19	covid-19	PROPN
dhrp-67	89	9	-	-	PUNCT
dhrp-67	89	10	rebound	rebound	NOUN
dhrp-67	89	11	-	-	PUNCT
dhrp-67	89	12	after	after	ADP
dhrp-67	89	13	-	-	PUNCT
dhrp-67	89	14	takingpaxlovid	takingpaxlovid	ADV
dhrp-67	89	15	-	-	PUNCT
dhrp-67	89	16	likely	likely	ADJ
dhrp-67	89	17	-	-	PUNCT
dhrp-67	89	18	due	due	ADJ
dhrp-67	89	19	-	-	PUNCT
dhrp-67	89	20	to	to	ADP
dhrp-67	89	21	-	-	PUNCT
dhrp-67	89	22	insufficient	insufficient	NOUN
dhrp-67	89	23	-	-	PUNCT
dhrp-67	89	24	drugexposure.aspx	drugexposure.aspx	NUM
dhrp-67	89	25	https://doi.org/10.1101/2022.06.21.22276724	https://doi.org/10.1101/2022.06.21.22276724	PROPN
dhrp-67	89	26	https://doi.org/10.1101/2022.06.21.22276724	https://doi.org/10.1101/2022.06.21.22276724	PROPN
dhrp-67	89	27	https://www.dailymail.co.uk/news/article-11065467/covid-reinfection-rate-treatment-biden-taking-40-not-2-marketed.html	https://www.dailymail.co.uk/news/article-11065467/covid-reinfection-rate-treatment-biden-taking-40-not-2-marketed.html	PROPN
dhrp-67	89	28	https://www.dailymail.co.uk/news/article-11065467/covid-reinfection-rate-treatment-biden-taking-40-not-2-marketed.html	https://www.dailymail.co.uk/news/article-11065467/covid-reinfection-rate-treatment-biden-taking-40-not-2-marketed.html	PROPN
dhrp-67	89	29	https://www.dailymail.co.uk/news/article-11065467/covid-reinfection-rate-treatment-biden-taking-40-not-2-marketed.html	https://www.dailymail.co.uk/news/article-11065467/covid-reinfection-rate-treatment-biden-taking-40-not-2-marketed.html	PROPN
dhrp-67	89	30	https://www.forbes.com/sites/brucelee/2022/06/30/dr-fauci-takes-2nd-course-of-paxlovid-after-suffering-covid-19-rebound/?sh=4964bf0315d6	https://www.forbes.com/sites/brucelee/2022/06/30/dr-fauci-takes-2nd-course-of-paxlovid-after-suffering-covid-19-rebound/?sh=4964bf0315d6	PROPN
dhrp-67	89	31	https://www.forbes.com/sites/brucelee/2022/06/30/dr-fauci-takes-2nd-course-of-paxlovid-after-suffering-covid-19-rebound/?sh=4964bf0315d6	https://www.forbes.com/sites/brucelee/2022/06/30/dr-fauci-takes-2nd-course-of-paxlovid-after-suffering-covid-19-rebound/?sh=4964bf0315d6	PROPN
dhrp-67	89	32	https://www.forbes.com/sites/brucelee/2022/06/30/dr-fauci-takes-2nd-course-of-paxlovid-after-suffering-covid-19-rebound/?sh=4964bf0315d6	https://www.forbes.com/sites/brucelee/2022/06/30/dr-fauci-takes-2nd-course-of-paxlovid-after-suffering-covid-19-rebound/?sh=4964bf0315d6	PROPN
dhrp-67	89	33	https://www.forbes.com/sites/brucelee/2022/06/30/dr-fauci-takes-2nd-course-of-paxlovid-after-suffering-covid-19-rebound/?sh=4964bf0315d6	https://www.forbes.com/sites/brucelee/2022/06/30/dr-fauci-takes-2nd-course-of-paxlovid-after-suffering-covid-19-rebound/?sh=4964bf0315d6	PROPN
dhrp-67	89	34	https://www.cnn.com/2022/07/31/politics/joe-biden-covid-positive-day-two/index.html	https://www.cnn.com/2022/07/31/politics/joe-biden-covid-positive-day-two/index.html	PROPN
dhrp-67	89	35	https://www.cnn.com/2022/07/31/politics/joe-biden-covid-positive-day-two/index.html	https://www.cnn.com/2022/07/31/politics/joe-biden-covid-positive-day-two/index.html	PROPN
dhrp-67	89	36	https://health.ucsd.edu/news/releases/pages/2022-06-21-covid-19-rebound-after-taking-paxlovid-likely-due-to-insufficient-drug-exposure.aspx	https://health.ucsd.edu/news/releases/pages/2022-06-21-covid-19-rebound-after-taking-paxlovid-likely-due-to-insufficient-drug-exposure.aspx	PROPN
dhrp-67	89	37	https://health.ucsd.edu/news/releases/pages/2022-06-21-covid-19-rebound-after-taking-paxlovid-likely-due-to-insufficient-drug-exposure.aspx	https://health.ucsd.edu/news/releases/pages/2022-06-21-covid-19-rebound-after-taking-paxlovid-likely-due-to-insufficient-drug-exposure.aspx	NUM
dhrp-67	89	38	https://health.ucsd.edu/news/releases/pages/2022-06-21-covid-19-rebound-after-taking-paxlovid-likely-due-to-insufficient-drug-exposure.aspx	https://health.ucsd.edu/news/releases/pages/2022-06-21-covid-19-rebound-after-taking-paxlovid-likely-due-to-insufficient-drug-exposure.aspx	PROPN
dhrp-67	89	39	https://health.ucsd.edu/news/releases/pages/2022-06-21-covid-19-rebound-after-taking-paxlovid-likely-due-to-insufficient-drug-exposure.aspx	https://health.ucsd.edu/news/releases/pages/2022-06-21-covid-19-rebound-after-taking-paxlovid-likely-due-to-insufficient-drug-exposure.aspx	PROPN
dhrp-67	89	40	rao	rao	PROPN
dhrp-67	89	41	,	,	PUNCT
dhrp-67	89	42	et	et	PROPN
dhrp-67	89	43	al	al	PROPN
dhrp-67	89	44	paxlovid	paxlovid	PROPN
dhrp-67	89	45	rebound	rebound	VERB
dhrp-67	89	46	https://doi.org/10.47488/dhrp.v2is3.67	https://doi.org/10.47488/dhrp.v2is3.67	PROPN
dhrp-67	89	47	dhr	dhr	PROPN
dhrp-67	89	48	proceedings	proceeding	NOUN
dhrp-67	89	49	ǀ	ǀ	ADP
dhrp-67	89	50	http://dhrproceedings.org	http://dhrproceedings.org	PROPN
dhrp-67	89	51	2022	2022	NUM
dhrp-67	89	52	,	,	PUNCT
dhrp-67	89	53	vol	vol	NOUN
dhrp-67	89	54	.	.	NOUN
dhrp-67	89	55	2	2	NUM
dhrp-67	90	1	no	no	NOUN
dhrp-67	90	2	.	.	PUNCT
dhrp-67	91	1	s3	s3	PROPN
dhrp-67	91	2	1	1	NUM
dhrp-67	91	3	-	-	SYM
dhrp-67	91	4	9	9	NUM
dhrp-67	91	5	5	5	NUM
dhrp-67	91	6	table	table	NOUN
dhrp-67	91	7	1	1	NUM
dhrp-67	91	8	:	:	PUNCT
dhrp-67	91	9	various	various	ADJ
dhrp-67	91	10	variants	variant	NOUN
dhrp-67	91	11	of	of	ADP
dhrp-67	91	12	omicron	omicron	PROPN
dhrp-67	91	13	since	since	SCONJ
dhrp-67	91	14	its	its	PRON
dhrp-67	91	15	first	first	ADJ
dhrp-67	91	16	identification	identification	NOUN
dhrp-67	91	17	in	in	ADP
dhrp-67	91	18	november	november	PROPN
dhrp-67	91	19	11	11	NUM
dhrp-67	91	20	,	,	PUNCT
dhrp-67	91	21	2022	2022	NUM
dhrp-67	91	22	and	and	CCONJ
dhrp-67	91	23	the	the	DET
dhrp-67	91	24	frequency	frequency	NOUN
dhrp-67	91	25	of	of	ADP
dhrp-67	91	26	patients	patient	NOUN
dhrp-67	91	27	infected	infect	VERB
dhrp-67	91	28	in	in	ADP
dhrp-67	91	29	the	the	DET
dhrp-67	91	30	united	united	PROPN
dhrp-67	91	31	states	states	PROPN
dhrp-67	91	32	as	as	ADP
dhrp-67	91	33	of	of	ADP
dhrp-67	91	34	july	july	PROPN
dhrp-67	91	35	23	23	NUM
dhrp-67	91	36	,	,	PUNCT
dhrp-67	91	37	2022	2022	NUM
dhrp-67	91	38	omicron	omicron	PROPN
dhrp-67	91	39	lineage	lineage	NOUN
dhrp-67	91	40	percentage	percentage	NOUN
dhrp-67	91	41	of	of	ADP
dhrp-67	91	42	patients	patient	NOUN
dhrp-67	91	43	infected	infect	VERB
dhrp-67	91	44	ba.1.1	ba.1.1	NOUN
dhrp-67	91	45	0.0	0.0	NUM
dhrp-67	91	46	%	%	NOUN
dhrp-67	91	47	ba.1.1.529	ba.1.1.529	ADP
dhrp-67	91	48	0.0	0.0	NUM
dhrp-67	91	49	%	%	NOUN
dhrp-67	91	50	ba.2	ba.2	NOUN
dhrp-67	91	51	0.3	0.3	NUM
dhrp-67	91	52	%	%	NOUN
dhrp-67	91	53	ba.2.12.1	ba.2.12.1	NOUN
dhrp-67	91	54	5.0	5.0	NUM
dhrp-67	91	55	%	%	NOUN
dhrp-67	91	56	ba.4	ba.4	NOUN
dhrp-67	91	57	12.9	12.9	NUM
dhrp-67	91	58	%	%	NOUN
dhrp-67	91	59	ba.5	ba.5	PROPN
dhrp-67	91	60	81.9	81.9	NUM
dhrp-67	91	61	%	%	NOUN
dhrp-67	91	62	rao	rao	NOUN
dhrp-67	91	63	,	,	PUNCT
dhrp-67	91	64	et	et	PROPN
dhrp-67	91	65	al	al	PROPN
dhrp-67	91	66	paxlovid	paxlovid	PROPN
dhrp-67	91	67	rebound	rebound	VERB
dhrp-67	91	68	https://doi.org/10.47488/dhrp.v2is3.67	https://doi.org/10.47488/dhrp.v2is3.67	PROPN
dhrp-67	91	69	dhr	dhr	PROPN
dhrp-67	91	70	proceedings	proceeding	NOUN
dhrp-67	91	71	ǀ	ǀ	ADP
dhrp-67	91	72	http://dhrproceedings.org	http://dhrproceedings.org	PROPN
dhrp-67	91	73	2022	2022	NUM
dhrp-67	91	74	,	,	PUNCT
dhrp-67	91	75	vol	vol	NOUN
dhrp-67	91	76	.	.	NOUN
dhrp-67	91	77	2	2	NUM
dhrp-67	92	1	no	no	NOUN
dhrp-67	92	2	.	.	PUNCT
dhrp-67	93	1	s3	s3	PROPN
dhrp-67	93	2	1	1	NUM
dhrp-67	93	3	-	-	SYM
dhrp-67	93	4	9	9	NUM
dhrp-67	93	5	6	6	NUM
dhrp-67	93	6	figure	figure	NOUN
dhrp-67	93	7	1	1	NUM
dhrp-67	93	8	:	:	PUNCT
dhrp-67	93	9	timeline	timeline	NOUN
dhrp-67	93	10	of	of	ADP
dhrp-67	93	11	various	various	ADJ
dhrp-67	93	12	omicron	omicron	NOUN
dhrp-67	93	13	lineages	lineage	NOUN
dhrp-67	93	14	causing	cause	VERB
dhrp-67	93	15	sars	sar	NOUN
dhrp-67	93	16	-	-	PUNCT
dhrp-67	93	17	cov-2	cov-2	PART
dhrp-67	93	18	infection	infection	NOUN
dhrp-67	93	19	in	in	ADP
dhrp-67	93	20	the	the	DET
dhrp-67	93	21	united	united	PROPN
dhrp-67	93	22	states	states	PROPN
dhrp-67	93	23	(	(	PUNCT
dhrp-67	93	24	adopted	adopt	VERB
dhrp-67	93	25	from	from	ADP
dhrp-67	93	26	cdc	cdc	PROPN
dhrp-67	93	27	website	website	NOUN
dhrp-67	93	28	):	):	PUNCT
dhrp-67	93	29	https://covid.cdc.gov/covid-data-tracker/#variant-proportions	https://covid.cdc.gov/covid-data-tracker/#variant-proportion	NOUN
dhrp-67	93	30	)	)	PUNCT
dhrp-67	93	31	https://covid.cdc.gov/covid-data-tracker/#variant-proportions	https://covid.cdc.gov/covid-data-tracker/#variant-proportions	PROPN
dhrp-67	93	32	rao	rao	PROPN
dhrp-67	93	33	,	,	PUNCT
dhrp-67	93	34	et	et	PROPN
dhrp-67	93	35	al	al	PROPN
dhrp-67	93	36	paxlovid	paxlovid	PROPN
dhrp-67	93	37	rebound	rebound	VERB
dhrp-67	93	38	https://doi.org/10.47488/dhrp.v2is3.67	https://doi.org/10.47488/dhrp.v2is3.67	PROPN
dhrp-67	93	39	dhr	dhr	PROPN
dhrp-67	93	40	proceedings	proceeding	NOUN
dhrp-67	93	41	ǀ	ǀ	ADP
dhrp-67	93	42	http://dhrproceedings.org	http://dhrproceedings.org	PROPN
dhrp-67	93	43	2022	2022	NUM
dhrp-67	93	44	,	,	PUNCT
dhrp-67	93	45	vol	vol	NOUN
dhrp-67	93	46	.	.	NOUN
dhrp-67	93	47	2	2	NUM
dhrp-67	94	1	no	no	NOUN
dhrp-67	94	2	.	.	PUNCT
dhrp-67	95	1	s3	s3	PROPN
dhrp-67	95	2	1	1	NUM
dhrp-67	95	3	-	-	SYM
dhrp-67	95	4	9	9	NUM
dhrp-67	95	5	7	7	NUM
dhrp-67	95	6	table	table	NOUN
dhrp-67	95	7	2	2	NUM
dhrp-67	95	8	:	:	PUNCT
dhrp-67	95	9	hospitalized	hospitalize	VERB
dhrp-67	95	10	and	and	CCONJ
dhrp-67	95	11	outpatient	outpatient	NOUN
dhrp-67	95	12	treatment	treatment	NOUN
dhrp-67	95	13	of	of	ADP
dhrp-67	95	14	patients	patient	NOUN
dhrp-67	95	15	infected	infect	VERB
dhrp-67	95	16	with	with	ADP
dhrp-67	95	17	the	the	DET
dhrp-67	95	18	ba.4	ba.4	PROPN
dhrp-67	95	19	and	and	CCONJ
dhrp-67	95	20	ba.5	ba.5	PROPN
dhrp-67	95	21	variants	variant	NOUN
dhrp-67	95	22	of	of	ADP
dhrp-67	95	23	omicron	omicron	PROPN
dhrp-67	95	24	experimental	experimental	ADJ
dhrp-67	95	25	drug	drug	PROPN
dhrp-67	95	26	inpatient	inpatient	PROPN
dhrp-67	95	27	vs.	vs.	ADP
dhrp-67	95	28	outpatient	outpatient	NOUN
dhrp-67	95	29	severity	severity	NOUN
dhrp-67	95	30	of	of	ADP
dhrp-67	95	31	disease	disease	NOUN
dhrp-67	95	32	reference	reference	NOUN
dhrp-67	95	33	bebtelovimab	bebtelovimab	NOUN
dhrp-67	95	34	monoclonal	monoclonal	NOUN
dhrp-67	95	35	antibody	antibody	NOUN
dhrp-67	95	36	outpatient	outpatient	NOUN
dhrp-67	95	37	mild	mild	NOUN
dhrp-67	95	38	to	to	AUX
dhrp-67	95	39	moderate	moderate	VERB
dhrp-67	95	40	https://www.fda.gov/media/156152/download	https://www.fda.gov/media/156152/download	X
dhrp-67	95	41	remdesivir	remdesivir	NOUN
dhrp-67	95	42	(	(	PUNCT
dhrp-67	95	43	velkury	velkury	PROPN
dhrp-67	95	44	)	)	PUNCT
dhrp-67	95	45	outpatient	outpatient	NOUN
dhrp-67	95	46	mild	mild	NOUN
dhrp-67	95	47	to	to	ADP
dhrp-67	95	48	moderate	moderate	ADJ
dhrp-67	95	49	https://www.fda.gov/news-events/pressannouncements/fda-takes-actions-expand-usetreatment-outpatients-mild-moderate-covid-19	https://www.fda.gov/news-events/pressannouncements/fda-takes-actions-expand-usetreatment-outpatients-mild-moderate-covid-19	PROPN
dhrp-67	95	50	remdesivir	remdesivir	NOUN
dhrp-67	95	51	+	+	CCONJ
dhrp-67	95	52	baricitinib	baricitinib	NOUN
dhrp-67	95	53	(	(	PUNCT
dhrp-67	95	54	olumiant	olumiant	ADJ
dhrp-67	95	55	)	)	PUNCT
dhrp-67	95	56	inpatient	inpatient	NOUN
dhrp-67	95	57	severe	severe	ADJ
dhrp-67	95	58	https://www.fda.gov/news-events/pressannouncements/coronavirus-covid-19-updatefda-authorizes-drug-combination-treatmentcovid-19	https://www.fda.gov/news-events/pressannouncements/coronavirus-covid-19-updatefda-authorizes-drug-combination-treatmentcovid-19	ADV
dhrp-67	95	59	ritonavir	ritonavir	PROPN
dhrp-67	95	60	-	-	PUNCT
dhrp-67	95	61	boosted	boost	VERB
dhrp-67	95	62	nirmatrelvir	nirmatrelvir	PROPN
dhrp-67	95	63	(	(	PUNCT
dhrp-67	95	64	paxlovid	paxlovid	PROPN
dhrp-67	95	65	)	)	PUNCT
dhrp-67	95	66	outpatient	outpatient	NOUN
dhrp-67	95	67	mild	mild	ADJ
dhrp-67	95	68	-	-	PUNCT
dhrp-67	95	69	moderate	moderate	ADJ
dhrp-67	95	70	https://www.paxlovid.com/?source=bing&hb	https://www.paxlovid.com/?source=bing&hb	NOUN
dhrp-67	95	71	x_pk	x_pk	PROPN
dhrp-67	96	1	=	=	X
dhrp-67	96	2	s_paxlovid&skwid=43700068281647	s_paxlovid&skwid=43700068281647	X
dhrp-67	96	3	229&gclid	229&gclid	PROPN
dhrp-67	96	4	=	=	PROPN
dhrp-67	96	5	c926586053d315737f663a86b321	c926586053d315737f663a86b321	PROPN
dhrp-67	96	6	0308&gclsrc=3p.ds	0308&gclsrc=3p.ds	PROPN
dhrp-67	96	7	malnupiravir	malnupiravir	PROPN
dhrp-67	96	8	(	(	PUNCT
dhrp-67	96	9	lagevrio	lagevrio	NOUN
dhrp-67	96	10	)	)	PUNCT
dhrp-67	96	11	outpatient	outpatient	NOUN
dhrp-67	96	12	mild	mild	ADJ
dhrp-67	96	13	-	-	PUNCT
dhrp-67	96	14	moderate	moderate	ADJ
dhrp-67	96	15	https://www.nejm.org/doi/full/10.1056/nejm	https://www.nejm.org/doi/full/10.1056/nejm	PROPN
dhrp-67	96	16	oa2116044	oa2116044	PROPN
dhrp-67	96	17	evusheldtm	evusheldtm	NOUN
dhrp-67	96	18	(	(	PUNCT
dhrp-67	96	19	tixagevimab	tixagevimab	NOUN
dhrp-67	96	20	and	and	CCONJ
dhrp-67	96	21	cilgavimab	cilgavimab	NOUN
dhrp-67	96	22	)	)	PUNCT
dhrp-67	96	23	outpatient	outpatient	NOUN
dhrp-67	96	24	pre	pre	NOUN
dhrp-67	96	25	-	-	NOUN
dhrp-67	96	26	exposure	exposure	ADJ
dhrp-67	96	27	prophylaxis	prophylaxis	NOUN
dhrp-67	96	28	in	in	ADP
dhrp-67	96	29	high	high	ADJ
dhrp-67	96	30	-	-	PUNCT
dhrp-67	96	31	risk	risk	NOUN
dhrp-67	96	32	patients	patient	NOUN
dhrp-67	96	33	https://www.evusheld.com/en/patient	https://www.evusheld.com/en/patient	AUX
dhrp-67	96	34	https://www.fda.gov/drugs/drug-safety-andavailability/fda-authorizes-revisionsevusheld-dosing	https://www.fda.gov/drugs/drug-safety-andavailability/fda-authorizes-revisionsevusheld-dose	VERB
dhrp-67	96	35	https://www.fda.gov/media/156152/download	https://www.fda.gov/media/156152/download	X
dhrp-67	96	36	https://www.fda.gov/news-events/press-announcements/fda-takes-actions-expand-use-treatment-outpatients-mild-moderate-covid-19	https://www.fda.gov/news-events/press-announcements/fda-takes-actions-expand-use-treatment-outpatients-mild-moderate-covid-19	ADV
dhrp-67	96	37	https://www.fda.gov/news-events/press-announcements/fda-takes-actions-expand-use-treatment-outpatients-mild-moderate-covid-19	https://www.fda.gov/news-events/press-announcements/fda-takes-actions-expand-use-treatment-outpatients-mild-moderate-covid-19	PROPN
dhrp-67	96	38	https://www.fda.gov/news-events/press-announcements/fda-takes-actions-expand-use-treatment-outpatients-mild-moderate-covid-19	https://www.fda.gov/news-events/press-announcements/fda-takes-actions-expand-use-treatment-outpatients-mild-moderate-covid-19	PROPN
dhrp-67	97	1	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19	PROPN
dhrp-67	97	2	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19	PROPN
dhrp-67	97	3	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19	PROPN
dhrp-67	97	4	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19	PROPN
dhrp-67	97	5	https://www.paxlovid.com/?source=bing&hbx_pk=s_paxlovid&skwid=43700068281647229&gclid=c926586053d315737f663a86b3210308&gclsrc=3p.ds	https://www.paxlovid.com/?source=bing&hbx_pk=s_paxlovid&skwid=43700068281647229&gclid=c926586053d315737f663a86b3210308&gclsrc=3p.ds	PROPN
dhrp-67	97	6	https://www.paxlovid.com/?source=bing&hbx_pk=s_paxlovid&skwid=43700068281647229&gclid=c926586053d315737f663a86b3210308&gclsrc=3p.ds	https://www.paxlovid.com/?source=bing&hbx_pk=s_paxlovid&skwid=43700068281647229&gclid=c926586053d315737f663a86b3210308&gclsrc=3p.ds	PROPN
dhrp-67	97	7	https://www.paxlovid.com/?source=bing&hbx_pk=s_paxlovid&skwid=43700068281647229&gclid=c926586053d315737f663a86b3210308&gclsrc=3p.ds	https://www.paxlovid.com/?source=bing&hbx_pk=s_paxlovid&skwid=43700068281647229&gclid=c926586053d315737f663a86b3210308&gclsrc=3p.ds	PROPN
dhrp-67	97	8	https://www.paxlovid.com/?source=bing&hbx_pk=s_paxlovid&skwid=43700068281647229&gclid=c926586053d315737f663a86b3210308&gclsrc=3p.ds	https://www.paxlovid.com/?source=bing&hbx_pk=s_paxlovid&skwid=43700068281647229&gclid=c926586053d315737f663a86b3210308&gclsrc=3p.ds	X
dhrp-67	97	9	https://www.nejm.org/doi/full/10.1056/nejmoa2116044	https://www.nejm.org/doi/full/10.1056/nejmoa2116044	PROPN
dhrp-67	98	1	https://www.nejm.org/doi/full/10.1056/nejmoa2116044	https://www.nejm.org/doi/full/10.1056/nejmoa2116044	PROPN
dhrp-67	98	2	https://www.evusheld.com/en/patient	https://www.evusheld.com/en/patient	NOUN
dhrp-67	98	3	https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-revisions-evusheld-dosing	https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-revisions-evusheld-dose	VERB
dhrp-67	98	4	https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-revisions-evusheld-dosing	https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-revisions-evusheld-dosing	PROPN
dhrp-67	98	5	https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-revisions-evusheld-dosing	https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-revisions-evusheld-dosing	PROPN
dhrp-67	98	6	rao	rao	NOUN
dhrp-67	98	7	,	,	PUNCT
dhrp-67	98	8	et	et	PROPN
dhrp-67	98	9	al	al	PROPN
dhrp-67	98	10	paxlovid	paxlovid	PROPN
dhrp-67	98	11	rebound	rebound	VERB
dhrp-67	98	12	https://doi.org/10.47488/dhrp.v2is3.67	https://doi.org/10.47488/dhrp.v2is3.67	PROPN
dhrp-67	98	13	dhr	dhr	PROPN
dhrp-67	98	14	proceedings	proceeding	NOUN
dhrp-67	98	15	ǀ	ǀ	ADP
dhrp-67	98	16	http://dhrproceedings.org	http://dhrproceedings.org	PROPN
dhrp-67	98	17	2022	2022	NUM
dhrp-67	98	18	,	,	PUNCT
dhrp-67	98	19	vol	vol	NOUN
dhrp-67	98	20	.	.	NOUN
dhrp-67	98	21	2	2	NUM
dhrp-67	99	1	no	no	NOUN
dhrp-67	99	2	.	.	PUNCT
dhrp-67	100	1	s3	s3	PROPN
dhrp-67	100	2	1	1	NUM
dhrp-67	100	3	-	-	SYM
dhrp-67	100	4	9	9	NUM
dhrp-67	100	5	8	8	NUM
dhrp-67	100	6	figure	figure	NOUN
dhrp-67	100	7	2	2	NUM
dhrp-67	100	8	:	:	PUNCT
dhrp-67	100	9	covid-19	covid-19	PROPN
dhrp-67	100	10	outpatient	outpatient	NOUN
dhrp-67	100	11	therapeutics	therapeutic	NOUN
dhrp-67	100	12	clinical	clinical	ADJ
dhrp-67	100	13	decision	decision	NOUN
dhrp-67	100	14	aid	aid	NOUN
dhrp-67	100	15	for	for	ADP
dhrp-67	100	16	ages	age	NOUN
dhrp-67	100	17	12	12	NUM
dhrp-67	100	18	+	+	NUM
dhrp-67	100	19	years	year	NOUN
dhrp-67	100	20	adult	adult	NOUN
dhrp-67	100	21	or	or	CCONJ
dhrp-67	100	22	pediatric	pediatric	ADJ
dhrp-67	100	23	patient	patient	NOUN
dhrp-67	100	24	(	(	PUNCT
dhrp-67	100	25	ages	age	NOUN
dhrp-67	100	26	12	12	NUM
dhrp-67	100	27	and	and	CCONJ
dhrp-67	100	28	older	old	ADJ
dhrp-67	100	29	weighing	weigh	VERB
dhrp-67	100	30	at	at	ADV
dhrp-67	100	31	least	least	ADV
dhrp-67	100	32	40	40	NUM
dhrp-67	100	33	kg	kg	NOUN
dhrp-67	100	34	)	)	PUNCT
dhrp-67	100	35	with	with	ADP
dhrp-67	100	36	mild	mild	ADJ
dhrp-67	100	37	to	to	PART
dhrp-67	100	38	moderate	moderate	VERB
dhrp-67	100	39	covid-19	covid-19	PROPN
dhrp-67	100	40	and	and	CCONJ
dhrp-67	100	41	at	at	ADP
dhrp-67	100	42	high	high	ADJ
dhrp-67	100	43	risk	risk	NOUN
dhrp-67	100	44	for	for	ADP
dhrp-67	100	45	progression	progression	NOUN
dhrp-67	100	46	to	to	ADP
dhrp-67	100	47	severe	severe	ADJ
dhrp-67	100	48	disease	disease	NOUN
dhrp-67	100	49	rao	rao	PROPN
dhrp-67	100	50	,	,	PUNCT
dhrp-67	100	51	et	et	PROPN
dhrp-67	100	52	al	al	PROPN
dhrp-67	100	53	paxlovid	paxlovid	PROPN
dhrp-67	100	54	rebound	rebound	VERB
dhrp-67	100	55	https://doi.org/10.47488/dhrp.v2is3.67	https://doi.org/10.47488/dhrp.v2is3.67	PROPN
dhrp-67	100	56	dhr	dhr	PROPN
dhrp-67	100	57	proceedings	proceeding	NOUN
dhrp-67	100	58	ǀ	ǀ	ADP
dhrp-67	100	59	http://dhrproceedings.org	http://dhrproceedings.org	PROPN
dhrp-67	100	60	2022	2022	NUM
dhrp-67	100	61	,	,	PUNCT
dhrp-67	100	62	vol	vol	NOUN
dhrp-67	100	63	.	.	NOUN
dhrp-67	100	64	2	2	NUM
dhrp-67	101	1	no	no	NOUN
dhrp-67	101	2	.	.	PUNCT
dhrp-67	102	1	s3	s3	PROPN
dhrp-67	102	2	1	1	NUM
dhrp-67	102	3	-	-	SYM
dhrp-67	102	4	9	9	NUM
dhrp-67	102	5	9	9	NUM
dhrp-67	102	6	figure	figure	NOUN
dhrp-67	102	7	3	3	NUM
dhrp-67	102	8	:	:	PUNCT
dhrp-67	102	9	covid-19	covid-19	PROPN
dhrp-67	102	10	outpatient	outpatient	NOUN
dhrp-67	102	11	therapeutics	therapeutic	NOUN
dhrp-67	102	12	18	18	NUM
dhrp-67	102	13	july	july	PROPN
dhrp-67	102	14	2022	2022	NUM
dhrp-67	102	15	clinical	clinical	ADJ
dhrp-67	102	16	decision	decision	NOUN
dhrp-67	102	17	aid	aid	NOUN
dhrp-67	102	18	for	for	ADP
dhrp-67	102	19	ages	age	NOUN
dhrp-67	102	20	28	28	NUM
dhrp-67	102	21	days	day	NOUN
dhrp-67	102	22	to	to	ADP
dhrp-67	102	23	less	less	ADJ
dhrp-67	102	24	than	than	ADP
dhrp-67	102	25	12	12	NUM
dhrp-67	102	26	years	year	NOUN
dhrp-67	102	27	pediatric	pediatric	ADJ
dhrp-67	102	28	patient	patient	NOUN
dhrp-67	102	29	(	(	PUNCT
dhrp-67	102	30	28	28	NUM
dhrp-67	102	31	days	day	NOUN
dhrp-67	102	32	of	of	ADP
dhrp-67	102	33	age	age	NOUN
dhrp-67	102	34	to	to	ADP
dhrp-67	102	35	less	less	ADJ
dhrp-67	102	36	than	than	ADP
dhrp-67	102	37	12	12	NUM
dhrp-67	102	38	years	year	NOUN
dhrp-67	102	39	,	,	PUNCT
dhrp-67	102	40	weighing	weigh	VERB
dhrp-67	102	41	at	at	ADV
dhrp-67	102	42	least	least	ADV
dhrp-67	102	43	3	3	NUM
dhrp-67	102	44	kg	kg	NOUN
dhrp-67	102	45	to	to	ADP
dhrp-67	102	46	less	less	ADJ
dhrp-67	102	47	than	than	ADP
dhrp-67	102	48	40	40	NUM
dhrp-67	102	49	kg	kg	NOUN
dhrp-67	102	50	)	)	PUNCT
dhrp-67	102	51	with	with	ADP
dhrp-67	102	52	mild	mild	ADJ
dhrp-67	102	53	to	to	PART
dhrp-67	102	54	moderate	moderate	VERB
dhrp-67	102	55	covid-19	covid-19	PROPN
dhrp-67	102	56	and	and	CCONJ
dhrp-67	102	57	at	at	ADP
dhrp-67	102	58	high	high	ADJ
dhrp-67	102	59	risk	risk	NOUN
dhrp-67	102	60	for	for	ADP
dhrp-67	102	61	progression	progression	NOUN
dhrp-67	102	62	to	to	ADP
dhrp-67	102	63	severe	severe	ADJ
dhrp-67	102	64	disease	disease	NOUN